Document:

<PAGE>
                                                                    Exhibit 10.5

                            MEDICAL DISCOVERIES, INC.

                            2002 STOCK INCENTIVE PLAN

        1. PURPOSE. The purpose of this 2002 Stock Incentive Plan (the "Plan")
is to enable Medical Discoveries, Inc. (the "Company") to attract and retain the
services of (i) selected employees, officers and directors of the Company or any
parent or subsidiary of the Company and (ii) selected nonemployee agents,
consultants, advisers and independent contractors of the Company or any parent
or subsidiary of the Company. For purposes of this Plan, a person is considered
to be employed by or in the service of the Company if the person is employed by
or in the service of any entity (the "Employer") that is either the Company or a
parent or subsidiary of the Company.

        2. SHARES SUBJECT TO THE PLAN. Subject to adjustment as provided below
and in Section 10, the shares to be offered under the Plan shall consist of
Common Stock of the Company, and the total number of shares of Common Stock that
may be issued under the Plan shall be 2,000,000 shares. If an option or
Performance-Based Award granted under the Plan expires, terminates or is
canceled, the unissued shares subject to that option or Performance-Based Award
shall again be available under the Plan. If shares awarded as a bonus pursuant
to Section 7 or sold pursuant to Section 8 under the Plan are forfeited to or
repurchased by the Company, the number of shares forfeited or repurchased shall
again be available under the Plan.

        3. EFFECTIVE DATE AND DURATION OF PLAN.

               3.1 EFFECTIVE DATE. The Plan shall become effective as of July
11, 2002. No Incentive Stock Option (as defined in Section 5 below) granted
under the Plan shall become exercisable and no payments shall be made under a
Performance-Based Award, however, until the Plan is approved by the affirmative
vote of the holders of a majority of the shares of Common Stock represented at a
shareholders meeting at which a quorum is present or by means of unanimous
consent resolutions, and the exercise of any Incentive Stock Options granted
under the Plan before approval shall be conditioned on and subject to that
approval. Subject to this limitation, options and Performance-Based Awards may
be granted and shares may be awarded as bonuses or sold under the Plan at any
time after the effective date and before termination of the Plan.

               3.2 DURATION. The Plan shall continue in effect until all shares
available for issuance under the Plan have been issued and all restrictions on
the shares have lapsed. The Board of Directors may suspend or terminate the Plan
at any time except with respect to options, Performance-Based Awards and shares
subject to restrictions then outstanding under the Plan. Termination shall not
affect any outstanding options, any outstanding Performance-Based Awards or any
right of the Company to repurchase shares or the forfeitability of shares issued
under the Plan.

<PAGE>

        4. ADMINISTRATION.

               4.1 BOARD OF DIRECTORS. The Plan shall be administered by the
Board of Directors of the Company, which shall determine and designate the
individuals to whom awards shall be made, the amount of the awards and the other
terms and conditions of the awards. Subject to the provisions of the Plan, the
Board of Directors may adopt and amend rules and regulations relating to
administration of the Plan, advance the lapse of any waiting period, accelerate
any exercise date, waive or modify any restriction applicable to shares (except
those restrictions imposed by law) and make all other determinations in the
judgment of the Board of Directors necessary or desirable for the administration
of the Plan. The interpretation and construction of the provisions of the Plan
and related agreements by the Board of Directors shall be final and conclusive.
The Board of Directors may correct any defect or supply any omission or
reconcile any inconsistency in the Plan or in any related agreement in the
manner and to the extent it deems expedient to carry the Plan into effect, and
the Board of Directors shall be the sole and final judge of such expediency.

               4.2 COMMITTEE. The Board of Directors may delegate to any
committee of the Board of Directors (the "Committee") any or all authority for
administration of the Plan. If authority is delegated to the Committee, all
references to the Board of Directors in the Plan shall mean and relate to the
Committee, except (i) as otherwise provided by the Board of Directors and (ii)
that only the Board of Directors may amend or terminate the Plan as provided in
Sections 3 and 11.

        5. TYPES OF AWARDS, ELIGIBILITY, LIMITATIONS. The Board of Directors
may, from time to time, take the following actions, separately or in
combination, under the Plan: (i) grant Incentive Stock Options, as defined in
Section 422 of the Internal Revenue Code of 1986, as amended (the "Code"), as
provided in Sections 6.1 and 6.2; (ii) grant options other than Incentive Stock
Options ("Non-Statutory Stock Options") as provided in Sections 6.1 and 6.3;
(iii) award stock bonuses as provided in Section 7; (iv) sell shares subject to
restrictions as provided in Section 8; and (v) award Performance-Based Awards as
provided in Section 9. Awards may be made to employees, including employees who
are officers or directors, and to other individuals described in Section 1
selected by the Board of Directors; provided, however, that only employees of
the Company or any parent or subsidiary of the Company (as defined in
subSections 424(e) and 424(f) of the Code) are eligible to receive Incentive
Stock Options under the Plan. The Board of Directors shall select the
individuals to whom awards shall be made and shall specify the action taken with
respect to each individual to whom an award is made. At the discretion of the
Board of Directors, an individual may be given an election to surrender an award
in exchange for the grant of a new award.

        6. OPTION GRANTS.

                6.1 GENERAL RULES RELATING TO OPTIONS.

                      6.1-1 TERMS OF GRANT. The Board of Directors may grant
options under the Plan. With respect to each option grant, the Board of
Directors shall determine the number of shares subject to the option, the
exercise price, the period of the option, the time or

                                       2
<PAGE>

times at which the option may be exercised and whether the option is an
Incentive Stock Option or a Non-Statutory Stock Option. At the time of the grant
of an option or at any time thereafter, the Board of Directors may provide that
an optionee who exercised an option with Common Stock of the Company shall
automatically receive a new option to purchase additional shares equal to the
number of shares surrendered and may specify the terms and conditions of such
new options.

                      6.1-2 EXERCISE OF OPTIONS. Except as provided in Section
6.1-4 or as determined by the Board of Directors, no option granted under the
Plan may be exercised unless at the time of exercise the optionee is employed by
or in the service of the Company and shall have been so employed or provided
such service continuously since the date the option was granted. Except as
provided in Sections 6.1-4 and 10, options granted under the Plan may be
exercised from time to time over the period stated in each option in amounts and
at times prescribed by the Board of Directors, provided that options may not be
exercised for fractional shares. Unless otherwise determined by the Board of
Directors, if an optionee does not exercise an option in any one year for the
full number of shares to which the optionee is entitled in that year, the
optionee's rights shall be cumulative and the optionee may purchase those shares
in any subsequent year during the term of the option.

                      6.1-3 NONTRANSFERABILITY. Each Incentive Stock Option and,
unless otherwise determined by the Board of Directors, each other option granted
under the Plan by its terms (i) shall be nonassignable and nontransferable by
the optionee, either voluntarily or by operation of law, except by will or by
the laws of descent and distribution of the state or country of the optionee's
domicile at the time of death, and (ii) during the optionee's lifetime, shall be
exercisable only by the optionee.

                      6.1-4 TERMINATION OF EMPLOYMENT OR SERVICE.

                             6.1-4(a) GENERAL RULE. Unless otherwise determined
by the Board of Directors, if an optionee's employment or service with the
Company terminates for any reason other than because of total disability or
death as provided in Sections 6.1-4(b) and (c), his or her option may be
exercised at any time before the expiration date of the option or the expiration
of 30 days after the date of termination, whichever is the shorter period, but
only if and to the extent the optionee was entitled to exercise the option at
the date of termination.

                             6.1-4(b) TERMINATION BECAUSE OF TOTAL DISABILITY.
Unless otherwise determined by the Board of Directors, if an optionee's
employment or service with the Company terminates because of total disability,
his or her option may be exercised at any time before the expiration date of the
option or before the date 12 months after the date of termination, whichever is
the shorter period, but only if and to the extent the optionee was entitled to
exercise the option at the date of termination. The term "total disability"
means a medically determinable mental or physical impairment that is expected to
result in death or has lasted or is expected to last for a continuous period of
12 months or more and that, in the opinion of the Company and two independent
physicians, causes the optionee to be unable to perform his or her duties as an
employee, director, officer or consultant of the Employer and

                                       3
<PAGE>

unable to be engaged in any substantial gainful activity. Total disability shall
be deemed to have occurred on the first day after the two independent physicians
have furnished their written opinion of total disability to the Company and the
Company has reached an opinion of total disability.

                             6.1-4(c) TERMINATION BECAUSE OF DEATH. Unless
otherwise determined by the Board of Directors, if an optionee dies while
employed by or providing service to the Company, his or her option may be
exercised at any time before the expiration date of the option or before the
date 12 months after the date of death, whichever is the shorter period, but
only if and to the extent the optionee was entitled to exercise the option at
the date of death and only by the person or persons to whom the optionee's
rights under the option shall pass by the optionee's will or by the laws of
descent and distribution of the state or country of domicile at the time of
death.

                             6.1-4(d) AMENDMENT OF EXERCISE PERIOD APPLICABLE TO
TERMINATION. The Board of Directors may at any time extend the 30-day and
12-month exercise periods any length of time not longer than the original
expiration date of the option. The Board of Directors may at any time increase
the portion of an option that is exercisable, subject to terms and conditions
determined by the Board of Directors.

                             6.1-4(e) FAILURE TO EXERCISE OPTION. To the extent
that the option of any deceased optionee or any optionee whose employment or
service terminates is not exercised within the applicable period, all further
rights to purchase shares pursuant to the option shall cease and terminate.

                             6.1-4(f) LEAVE OF ABSENCE. Absence on leave
approved by the Employer or on account of illness or disability shall not be
deemed a termination or interruption of employment or service. Unless otherwise
determined by the Board of Directors, vesting of options shall continue during a
medical, family or military leave of absence, whether paid or unpaid, and
vesting of options shall be suspended during any other unpaid leave of absence.

                      6.1-5 PURCHASE OF SHARES.

                             6.1-5(a) NOTICE OF EXERCISE. Unless the Board of
Directors determines otherwise, shares may be acquired pursuant to an option
granted under the Plan only upon the Company's receipt of written notice from
the optionee of the optionee's binding commitment to purchase shares, specifying
the number of shares the optionee desires to purchase under the option and the
date on which the optionee agrees to complete the transaction, and, if required
to comply with the Securities Act of 1933, containing a representation that it
is the optionee's intention to acquire the shares for investment and not with a
view to distribution.

                             6.1-5(b) PAYMENT. Unless the Board of Directors
determines otherwise, on or before the date specified for completion of the
purchase of shares pursuant to an option exercise, the optionee must pay the
Company the full purchase price of those shares

                                       4
<PAGE>

in cash or by check or, with the consent of the Board of Directors, in whole or
in part, in Common Stock of the Company valued at fair market value, restricted
stock or other contingent awards denominated in either stock or cash, promissory
notes and other forms of consideration. Unless otherwise determined by the Board
of Directors, any Common Stock provided in payment of the purchase price must
have been previously acquired and held by the optionee for at least six months.
The fair market value of Common Stock provided in payment of the purchase price
shall be the closing price of the Common Stock last reported before the time
payment in Common Stock is made or, if earlier, committed to be made, if the
Common Stock is publicly traded, or another value of the Common Stock as
specified by the Board of Directors. No shares shall be issued until full
payment for the shares has been made, including all amounts owed for tax
withholding. With the consent of the Board of Directors, an optionee may request
the Company to apply automatically the shares to be received upon the exercise
of a portion of a stock option (even though stock certificates have not yet been
issued) to satisfy the purchase price for additional portions of the option.

                             6.1-5(c) TAX WITHHOLDING. Each optionee who has
exercised an option shall, immediately upon notification of the amount due, if
any, pay to the Company in cash or by check amounts necessary to satisfy any
applicable federal, state and local tax withholding requirements. If additional
withholding is or becomes required (as a result of exercise of an option or as a
result of disposition of shares acquired pursuant to exercise of an option)
beyond any amount deposited before delivery of the certificates, the optionee
shall pay such amount, in cash or by check, to the Company on demand. If the
optionee fails to pay the amount demanded, the Company or the Employer may
withhold that amount from other amounts payable to the optionee, including
salary, subject to applicable law. With the consent of the Board of Directors,
an optionee may satisfy this obligation, in whole or in part, by instructing the
Company to withhold from the shares to be issued upon exercise or by delivering
to the Company other shares of Common Stock; provided, however, that the number
of shares so withheld or delivered shall not exceed the minimum amount necessary
to satisfy the required withholding obligation.

                             6.1-5(d) REDUCTION OF RESERVED SHARES. Upon the
exercise of an option, the number of shares reserved for issuance under the Plan
shall be reduced by the number of shares issued upon exercise of the option
(less the number of any shares surrendered in payment for the exercise price or
withheld to satisfy withholding requirements).

                      6.1-6 LIMITATIONS ON GRANTS TO NON-EXEMPT EMPLOYEES.
Unless otherwise determined by the Board of Directors, if an employee of the
Company or any parent or subsidiary of the Company is a non-exempt employee
subject to the overtime compensation provisions of Section 7 of the Fair Labor
Standards Act (the "FLSA"), any option granted to that employee shall be subject
to the following restrictions: (i) the option price shall be at least 85 percent
of the fair market value, as described in Section 6.2-4, of the Common Stock
subject to the option on the date it is granted; and (ii) the option shall not
be exercisable until at least six months after the date it is granted; provided,
however, that this six-month restriction on exercisability will cease to apply
if the employee dies, becomes disabled or retires, there is

                                       5
<PAGE>

a change in ownership of the Company, or in other circumstances permitted by
regulation, all as prescribed in Section 7(e)(8)(B) of the FLSA.

               6.2 INCENTIVE STOCK OPTIONS. Incentive Stock Options shall be
subject to the following additional terms and conditions:

                      6.2-1 LIMITATION ON AMOUNT OF GRANTS. If the aggregate
fair market value of stock (determined as of the date the option is granted) for
which Incentive Stock Options granted under this Plan (and any other stock
incentive plan of the Company or its parent or subsidiary corporations, as
defined in subSections 424(e) and 424(f) of the Code) are exercisable for the
first time by an employee during any calendar year exceeds $100,000, the portion
of the option or options not exceeding $100,000, to the extent of whole shares,
will be treated as an Incentive Stock Option and the remaining portion of the
option or options will be treated as a Non-Statutory Stock Option. The preceding
sentence will be applied by taking options into account in the order in which
they were granted. If, under the $100,000 limitation, a portion of an option is
treated as an Incentive Stock Option and the remaining portion of the option is
treated as a Non-Statutory Stock Option, unless the optionee designates
otherwise at the time of exercise, the optionee's exercise of all or a portion
of the option will be treated as the exercise of the Incentive Stock Option
portion of the option to the full extent permitted under the $100,000
limitation. If an optionee exercises an option that is treated as in part an
Incentive Stock Option and in part a Non-Statutory Stock Option, the Company
will designate the portion of the stock acquired pursuant to the exercise of the
Incentive Stock Option portion as Incentive Stock Option stock by issuing a
separate certificate for that portion of the stock and identifying the
certificate as Incentive Stock Option stock in its stock records.

                      6.2-2 LIMITATIONS ON GRANTS TO 10 PERCENT SHAREHOLDERS. An
Incentive Stock Option may be granted under the Plan to an employee possessing
more than 10 percent of the total combined voting power of all classes of stock
of the Company or any parent or subsidiary (as defined in subSections 424(e) and
424(f) of the Code) only if the option price is at least 110 percent of the fair
market value, as described in Section 6.2-4, of the Common Stock subject to the
option on the date it is granted and the option by its terms is not exercisable
after the expiration of five years from the date it is granted.

                      6.2-3 DURATION OF OPTIONS. Subject to Sections 6.1-2,
6.1-4 and 6.2-2, Incentive Stock Options granted under the Plan shall continue
in effect for the period fixed by the Board of Directors, except that by its
terms no Incentive Stock Option shall be exercisable after the expiration of 10
years from the date it is granted.

                      6.2-4 OPTION PRICE. The option price per share shall be
determined by the Board of Directors at the time of grant. Except as provided in
Section 6.2-2, the option price shall not be less than 100 percent of the fair
market value of the Common Stock covered by the Incentive Stock Option at the
date the option is granted. The fair market value shall be the closing price of
the Common Stock last reported before the time the option is granted, if the
stock is publicly traded, or another value of the Common Stock as specified by
the Board of Directors.

                                       6
<PAGE>

                      6.2-5 LIMITATION ON TIME OF GRANT. No Incentive Stock
Option shall be granted on or after the tenth anniversary of the last action by
the Board of Directors adopting the Plan or approving an increase in the number
of shares available for issuance under the Plan, which action was subsequently
approved within 12 months by the shareholders.

                      6.2-6 EARLY DISPOSITIONS. If within two years after an
Incentive Stock Option is granted or within 12 months after an Incentive Stock
Option is exercised, the optionee sells or otherwise disposes of Common Stock
acquired on exercise of the Option, the optionee shall within 30 days of the
sale or disposition notify the Company in writing of (i) the date of the sale or
disposition, (ii) the amount realized on the sale or disposition and (iii) the
nature of the disposition (e.g., sale, gift, etc.).

               6.3 NON-STATUTORY STOCK OPTIONS. Non-Statutory Stock Options
shall be subject to the following terms and conditions, in addition to those set
forth in Section 6.1 above:

                      6.3-1 OPTION PRICE. The option price for Non-Statutory
Stock Options shall be determined by the Board of Directors at the time of grant
and may be any amount determined by the Board of Directors.

                      6.3-2 DURATION OF OPTIONS. Non-Statutory Stock Options
granted under the Plan shall continue in effect for the period fixed by the
Board of Directors.

        7. STOCK BONUSES. The Board of Directors may award shares under the Plan
as stock bonuses. Shares awarded as a bonus shall be subject to the terms,
conditions and restrictions determined by the Board of Directors. The
restrictions may include restrictions concerning transferability and forfeiture
of the shares awarded, together with any other restrictions determined by the
Board of Directors. The Board of Directors may require the recipient to sign an
agreement as a condition of the award, but may not require the recipient to pay
any monetary consideration other than amounts necessary to satisfy tax
withholding requirements. The agreement may contain any terms, conditions,
restrictions, representations and warranties required by the Board of Directors.
The certificates representing the shares awarded shall bear any legends required
by the Board of Directors. The Company may require any recipient of a stock
bonus to pay to the Company in cash or by check upon demand amounts necessary to
satisfy any applicable federal, state or local tax withholding requirements. If
the recipient fails to pay the amount demanded, the Company or the Employer may
withhold that amount from other amounts payable to the recipient, including
salary, subject to applicable law. With the consent of the Board of Directors, a
recipient may satisfy this obligation, in whole or in part, by instructing the
Company to withhold from any shares to be issued or by delivering to the Company
other shares of Common Stock; provided, however, that the number of shares so
withheld or delivered shall not exceed the minimum amount necessary to satisfy
the required withholding obligation. Upon the issuance of a stock bonus, the
number of shares reserved for issuance under the Plan shall be reduced by the
number of shares issued, less the number of shares withheld or delivered to
satisfy withholding obligations.

                                       7
<PAGE>

        8. RESTRICTED STOCK. The Board of Directors may issue shares under the
Plan for any consideration (including promissory notes and services) determined
by the Board of Directors. Shares issued under the Plan shall be subject to the
terms, conditions and restrictions determined by the Board of Directors. The
restrictions may include restrictions concerning transferability, repurchase by
the Company and forfeiture of the shares issued, together with any other
restrictions determined by the Board of Directors. All Common Stock issued
pursuant to this Section 8 shall be subject to a purchase agreement, which shall
be executed by the Company and the prospective purchaser of the shares before
the delivery of certificates representing the shares to the purchaser. The
purchase agreement may contain any terms, conditions, restrictions,
representations and warranties required by the Board of Directors. The
certificates representing the shares shall bear any legends required by the
Board of Directors. The Company may require any purchaser of restricted stock to
pay to the Company in cash or by check upon demand amounts necessary to satisfy
any applicable federal, state or local tax withholding requirements. If the
purchaser fails to pay the amount demanded, the Company or the Employer may
withhold that amount from other amounts payable to the purchaser, including
salary, subject to applicable law. With the consent of the Board of Directors, a
purchaser may satisfy this obligation, in whole or in part, by instructing the
Company to withhold from any shares to be issued or by delivering to the Company
other shares of Common Stock; provided, however, that the number of shares so
withheld or delivered shall not exceed the minimum amount necessary to satisfy
the required withholding obligation. Upon the issuance of restricted stock, the
number of shares reserved for issuance under the Plan shall be reduced by the
number of shares issued, less the number of shares withheld or delivered to
satisfy withholding obligations.

        9. PERFORMANCE-BASED AWARDS. The Board of Directors may grant awards
intended to qualify as qualified performance-based compensation under Section
162(m) of the Code and the regulations thereunder ("Performance-Based Awards").
Performance-Based Awards shall be denominated at the time of grant either in
Common Stock ("Stock Performance Awards") or in dollar amounts ("Dollar
Performance Awards"). Payment under a Stock Performance Award or a Dollar
Performance Award shall be made, at the discretion of the Board of Directors, in
Common Stock ("Performance Shares"), or in cash or in any combination thereof.
Performance-Based Awards shall be subject to the following terms and conditions:

               9.1 AWARD PERIOD. The Board of Directors shall determine the
period of time for which a Performance-Based Award is made (the "Award Period").

               9.2 PERFORMANCE GOALS AND PAYMENT. The Board of Directors shall
establish in writing objectives ("Performance Goals") that must be met by the
Company or any subsidiary, division or other unit of the Company ("Business
Unit") during the Award Period as a condition to payment being made under the
Performance-Based Award. The Performance Goals for each award shall be one or
more targeted levels of performance with respect to one or more of the following
objective measures with respect to the Company or any Business Unit: earnings,
earnings per share, stock price increase, total shareholder return (stock price
increase plus dividends), return on equity, return on assets, return on capital,
economic value

                                       8
<PAGE>

added, revenues, operating income, inventories, inventory turns, cash flows or
any of the foregoing before the effect of acquisitions, divestitures, accounting
changes, and restructuring and special charges (determined according to criteria
established by the Board of Directors). The Board of Directors shall also
establish the number of Performance Shares or the amount of cash payment to be
made under a Performance-Based Award if the Performance Goals are met or
exceeded, including the fixing of a maximum payment. The Board of Directors may
establish other restrictions to payment under a Performance-Based Award, such as
a continued employment requirement, in addition to satisfaction of the
Performance Goals. Some or all of the Performance Shares may be issued at the
time of the award as restricted shares subject to forfeiture in whole or in part
if Performance Goals or, if applicable, other restrictions are not satisfied.

               9.3 COMPUTATION OF PAYMENT. During or after an Award Period, the
performance of the Company or Business Unit, as applicable, during the period
shall be measured against the Performance Goals. If the Performance Goals are
not met, no payment shall be made under a Performance-Based Award. If the
Performance Goals are met or exceeded, the Board of Directors shall certify that
fact in writing and certify the number of Performance Shares earned or the
amount of cash payment to be made under the terms of the Performance-Based
Award.

               9.4 TAX WITHHOLDING. Each participant who has received
Performance Shares shall, upon notification of the amount due, pay to the
Company in cash or by check amounts necessary to satisfy any applicable federal,
state and local tax withholding requirements. If the participant fails to pay
the amount demanded, the Company or the Employer may withhold that amount from
other amounts payable to the participant, including salary, subject to
applicable law. With the consent of the Board of Directors, a participant may
satisfy this obligation, in whole or in part, by instructing the Company to
withhold from any shares to be issued or by delivering to the Company other
shares of Common Stock; provided, however, that the number of shares so
delivered or withheld shall not exceed the minimum amount necessary to satisfy
the required withholding obligation.

               9.5 EFFECT ON SHARES AVAILABLE. The payment of a
Performance-Based Award in cash shall not reduce the number of shares of Common
Stock reserved for issuance under the Plan. The number of shares of Common Stock
reserved for issuance under the Plan shall be reduced by the number of shares
issued upon payment of an award, less the number of shares delivered or withheld
to satisfy withholding obligations.

        10. CHANGES IN CAPITAL STRUCTURE.

               10.1 STOCK SPLITS, STOCK DIVIDENDS. If the outstanding Common
Stock of the Company is hereafter increased or decreased or changed into or
exchanged for a different number or kind of shares or other securities of the
Company by reason of any stock split, combination of shares, dividend payable in
shares, recapitalization or reclassification, appropriate adjustment shall be
made by the Board of Directors in the number and kind of shares available for
grants under the Plan and in all other share amounts set forth in the Plan. In
addition, the Board of Directors shall make appropriate adjustment in the number
and kind

                                       9
<PAGE>

of shares as to which outstanding options, or portions thereof then unexercised,
shall be exercisable, so that the optionee's proportionate interest before and
after the occurrence of the event is maintained. Notwithstanding the foregoing,
the Board of Directors shall have no obligation to effect any adjustment that
would or might result in the issuance of fractional shares, and any fractional
shares resulting from any adjustment may be disregarded or provided for in any
manner determined by the Board of Directors. Any such adjustments made by the
Board of Directors shall be conclusive.

               10.2 MERGERS, REORGANIZATIONS, ETC. In the event of a merger,
consolidation, plan of exchange, acquisition of property or stock, split-up,
split-off, spin-off, reorganization or liquidation to which the Company is a
party or any sale, lease, exchange or other transfer (in one transaction or a
series of related transactions) of all, or substantially all, of the assets of
the Company (each, a "Transaction"), the Board of Directors shall, in its sole
discretion and to the extent possible under the structure of the Transaction,
select one of the following alternatives for treating outstanding options under
the Plan:

                      10.2-1 Outstanding options shall remain in effect in
accordance with their terms.

                      10.2-2 Outstanding options shall be converted into options
to purchase stock in one or more of the corporations, including the Company,
that are the surviving or acquiring corporations in the Transaction. The amount,
type of securities subject thereto and exercise price of the converted options
shall be determined by the Board of Directors of the Company, taking into
account the relative values of the companies involved in the Transaction and the
exchange rate, if any, used in determining shares of the surviving
corporation(s) to be held by holders of shares of the Company following the
Transaction. Unless otherwise determined by the Board of Directors, the
converted options shall be vested only to the extent that the vesting
requirements relating to options granted hereunder have been satisfied.

                      10.2-3 The Board of Directors shall provide a period of 30
days or less before the completion of the Transaction during which outstanding
options may be exercised to the extent then exercisable, and upon the expiration
of that period, all unexercised options shall immediately terminate. The Board
of Directors may, in its sole discretion, accelerate the exercisability of
options so that they are exercisable in full during that period.

               10.3 DISSOLUTION OF THE COMPANY. In the event of the dissolution
of the Company, options shall be treated in accordance with Section 10.2-3.

               10.4 RIGHTS ISSUED BY ANOTHER CORPORATION. The Board of Directors
may also grant options and stock bonuses and Performance-Based Awards and issue
restricted stock under the Plan with terms, conditions and provisions that vary
from those specified in the Plan, provided that any such awards are granted in
substitution for, or in connection with the assumption of, existing options,
stock bonuses, Performance-Based Awards and restricted stock granted, awarded or
issued by another corporation and assumed or otherwise agreed to be provided for
by the Company pursuant to or by reason of a Transaction.

                                       10
<PAGE>

        11. AMENDMENT OF THE PLAN. The Board of Directors may at any time modify
or amend the Plan in any respect. Except as provided in Section 10, however, no
change in an award already granted shall be made without the written consent of
the holder of the award if the change would adversely affect the holder.

        12. APPROVALS. The Company's obligations under the Plan are subject to
the approval of state and federal authorities or agencies with jurisdiction in
the matter. The Company will use its best efforts to take steps required by
state or federal law or applicable regulations, including rules and regulations
of the Securities and Exchange Commission and any stock exchange on which the
Company's shares may then be listed, in connection with the grants under the
Plan. The foregoing notwithstanding, the Company shall not be obligated to issue
or deliver Common Stock under the Plan if such issuance or delivery would
violate state or federal securities laws.

        13. EMPLOYMENT AND SERVICE RIGHTS. Nothing in the Plan or any award
pursuant to the Plan shall (i) confer upon any employee any right to be
continued in the employment of an Employer or interfere in any way with the
Employer's right to terminate the employee's employment at will at any time, for
any reason, with or without cause, or to decrease the employee's compensation or
benefits, or (ii) confer upon any person engaged by an Employer any right to be
retained or employed by the Employer or to the continuation, extension, renewal
or modification of any compensation, contract or arrangement with or by the
Employer.

        14. RIGHTS AS A SHAREHOLDER. The recipient of any award under the Plan
shall have no rights as a shareholder with respect to any shares of Common Stock
until the date the recipient becomes the holder of record of those shares.
Except as otherwise expressly provided in the Plan, no adjustment shall be made
for dividends or other rights for which the record date occurs before the date
the recipient becomes the holder of record.

Adopted: July 11, 2002

                                       11<PAGE>

                                                                    EXHIBIT 10.1

                                LICENSE AGREEMENT

                                     BETWEEN

                                   ZYCOS INC.

                                       AND

                           COHESION TECHNOLOGIES, INC.

                         EFFECTIVE AS OF MARCH 15, 2002

<PAGE>

                         RESEARCH AND LICENSE AGREEMENT

            THIS RESEARCH AND LICENSE AGREEMENT (this "Agreement") is made and
entered into effective as of March 15, 2002 (the "Effective Date"), by and
between ZYCOS INC., a Delaware corporation, having its principal place of
business at 44 Hartwell Avenue, Lexington, Massachusetts 02421 ("ZYCOS"), and
COHESION TECHNOLOGIES, INC., a Delaware corporation with its principal place of
business at 2500 Faber Place, Palo Alto, California 94303 ("Cohesion").

                                    RECITALS

            WHEREAS, Cohesion has certain patent and other rights with respect
to the method (the "Method") of Manufacturing (as defined below) and using
cross-linked polymer compositions ("Hydrogels"); and

            WHEREAS, Cohesion desires to license ZYCOS, and ZYCOS desires to
obtain a license, under such patents and other rights to develop and
commercialize products employing the Method in accordance with the terms and
conditions set forth below.

            NOW, THEREFORE, in consideration of the foregoing premises, the
mutual promises and covenants of the parties hereinafter set forth, and other
good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto, intending to be legally bound, do hereby agree
as follows:

                                    ARTICLE I
                                   DEFINITIONS

            Unless otherwise specifically provided herein, the following terms
shall have the following meanings:

            1.1 "AFFILIATE"

with respect to a Person, shall mean any other Person that directly, or
indirectly through one or more intermediaries, controls, is controlled by or is
under common control with such Person. For purposes of this Section 1.1 only,
"control" and, with correlative meanings, the terms "controlled by" and "under
common control with" shall mean the ownership, directly or indirectly, of at
least fifty percent (50%) (or, if less, the maximum ownership interest permitted
by law) of the voting securities or other ownership interest of a Person.

            1.2 "APPLICABLE LAW"

shall mean the applicable laws, rules, regulations, guidelines and requirements
of the Regulatory Authorities in the Territory.

            1.3 "CALENDAR QUARTER"

shall mean each period of three consecutive calendar months ending on March 31,
June 30, September 30 and December 31.

<PAGE>

            1.4 "CALENDAR YEAR"

shall mean each successive period of twelve months commencing on January 1 and
ending on December 31.

            1.5 "COHESION"

shall have the meaning set forth in the preamble of this Agreement.

            1.6 "COHESION KNOW-HOW"

shall mean any and all Information and Inventions developed by or on behalf of
Cohesion prior to the Effective Date or during the term of this Agreement, or
that Cohesion otherwise Controls as of the Effective Date or during the term of
this Agreement, that relate to the Method, the Hydrogels or Improvements to any
of the foregoing, but excluding any Information and Inventions to the extent
covered or claimed by the Cohesion Patents.

            1.7 "COHESION PATENTS"

shall mean all of the Patents that Cohesion owns or otherwise Controls as of the
Effective Date or at any time during the term of this Agreement, that relate to
the Method, the Hydrogels or Improvements to any of the foregoing.

            1.8 "CONFIDENTIAL INFORMATION"

shall have the meaning set forth in Section 7.1(a).

            1.9 "CONTROL"

shall mean, with respect to any item of Information and Invention, Patent or
other intellectual property right, the right, whether by ownership, license or
otherwise, to grant a license, sublicense or other right to or under, such item,
Patent or right as provided for herein without violating the terms of any
agreement or other arrangement with any Third Party.

            1.10 "CURE PERIOD"

shall have the meaning set forth in Section 8.2.

            1.11 "EFFECTIVE DATE"

shall mean the effective date of this Agreement as set forth in the preamble to
this Agreement.

            1.12 "EXPLOIT"

shall mean to make, have made, import, use, sell, offer for sale or otherwise
dispose, including to research, develop, modify, enhance, improve, Manufacture,
have Manufactured, store, formulate, have used, export, transport, distribute,
promote, market or have sold.

<PAGE>

            1.13 "EXPLOITATION"

shall mean the making, having made, importation, use, sale, offering for sale or
disposition of a product or process, including the research, development,
modification, enhancement, improvement, Manufacture, storage, formulation,
optimization, import, export, transport, distribution, promotion or marketing of
a product or process.

            1.14 "FDA"

shall mean the United States Food and Drug Administration and any successor
agency thereto.

            1.15 "FIELD"

shall mean the treatment and prevention of human diseases, disorders and
conditions.

            1.16 "HYDROGELS"

shall have the meaning set forth in the Recitals to this Agreement.

            1.17 "IMPROVEMENT"

shall mean any modification, variation or revision to a product or any
discovery, technology, device, process or formulation related to such product,
whether or not patented or patentable, including any enhancement in the
Manufacture or steps or processes thereof, ingredients, preparation,
presentation, formulation, means of delivery, packaging or dosage of such
product, any discovery or development of any new or expanded indications for
such product, or any discovery or development that improves the stability,
safety or efficacy of such product.

            1.18 "IND"

shall mean an investigational new drug application filed with the FDA for
approval to commence human clinical trials, and its equivalent in other
countries or regulatory jurisdictions in the Territory.

            1.19 "INDEMNIFICATION CLAIM NOTICE"

shall have the meaning set forth in Section 9.3(a).

            1.20 "INDEMNIFIED PARTY"

shall have the meaning set forth in Section 9.3(a).

            1.21 "INFORMATION AND INVENTIONS"

shall mean all technical, scientific and other know-how and information, trade
secrets, knowledge, technology, means, methods, processes, practices, formulas,
instructions, skills, techniques, procedures, experiences, ideas, technical
assistance, designs, drawings, assembly

<PAGE>

procedures, computer programs, apparatuses, specifications, data, results and
other material, including pre-clinical and clinical trial results, manufacturing
procedures, test procedures and purification and isolation techniques, (whether
or not confidential, proprietary, patented or patentable) in written, electronic
or any other form now known or hereafter developed, and all Improvements,
whether to the foregoing or otherwise, and other discoveries, developments,
inventions, and other intellectual property (whether or not confidential,
proprietary, patented or patentable).

            1.22 "LICENSED TECHNOLOGY"

shall mean, collectively, the Cohesion Patents and the Cohesion Know-How.

            1.23 "LOSSES"

shall have the meaning set forth in Section 9.1.

            1.24 "MANUFACTURE" AND "MANUFACTURING"

shall mean, with respect to a product, compound or hydrogel, the manufacturing,
processing, formulating, packaging, labeling, holding and quality control
testing of such product, compound or hydrogel.

            1.25 "METHOD"

shall have the meaning set forth in the Recitals to this Agreement.

            1.26 "NDA"

shall mean a New Drug Application filed pursuant to the requirements of the FDA,
as more fully defined in 21 C.F.R. Section 314.5 et seq., and any equivalent
application required by any Regulatory Authority for the marketing, sale or use
of the Products in the Territory.

            1.27 "NET SALES"

shall mean, for any period, the gross amount invoiced by ZYCOS and its
Affiliates or sublicensees for the sale of Products by ZYCOS or its Affiliates
or sublicensees to Third Parties, less deductions for: (a) normal and customary
trade, quantity and cash discounts and sales returns and allowances, including
(i) those granted on account of price adjustments, billing errors, rejected
goods, damaged goods, returns and rebates, (ii) administrative and other fees
and reimbursements and similar payments to wholesalers and other distributors,
buying groups, pharmacy benefit management organizations, health care insurance
carriers and other institutions, (iii) allowances, rebates and fees paid to
distributors and (iv) chargebacks; (b) freight, postage, shipping and insurance
expenses to the extent that such items are separately included in the gross
amount invoiced; (c) customs and excise duties and other duties related to the
sales to the extent that such items are separately included in the gross amount
invoiced; (d) rebates and similar payments made with respect to sales paid for
by any governmental or regulatory authority such as, by way of illustration and
not in limitation of the parties' rights

<PAGE>

hereunder, Federal or state Medicaid, Medicare or similar state program or
equivalent foreign governmental program; (e) sales and other taxes and duties
directly related to the sale or delivery of Product (but not including taxes
assessed against the income derived from such sale); (f) distribution expenses
to the extent that such items are separately included in the gross amount
invoiced; (g) any other similar and customary deductions that are consistent
with United States generally accepted accounting principles, or in the case of
non-United States sales, other applicable accounting standards; and (h) any such
invoiced amounts that are not collected by ZYCOS or its Affiliates or
sublicensees. ZYCOS shall keep adequate written records of any such invoiced
amounts and such deductions (the "Written Records"). Any of the deductions
listed above that involves a payment by ZYCOS or its Affiliates or sublicensees
shall be taken as a deduction in the Calendar Quarter in which the payment is
accrued by such entity. For purposes of determining Net Sales, the Product shall
be deemed to be sold when invoiced and a "sale" shall not include transfers or
dispositions for charitable, promotional, pre-clinical, clinical, regulatory or
governmental purposes (except to the extent that such transfers or dispositions
directly generate income).

            For purposes of calculating Net Sales, sales between or among ZYCOS
or its Affiliates or sublicensees for resale shall be excluded from the
computation of Net Sales, but sales by ZYCOS or its Affiliates or sublicensees
to Third Parties shall be included in the computation of Net Sales.

            In the event that a Product is sold in any country in the form of a
combination product containing one or more therapeutically active ingredients in
addition to those found in the version of the Product initially commercialized
by ZYCOS or its Affiliates or sublicensees in the United States, Net Sales of
such combination product will be adjusted by multiplying actual Net Sales of
such combination product in such country calculated pursuant to the first
paragraph of this Section 1.27 by the fraction A/(A+B), where A is the average
invoice price in such country of the Product sold without such other active
ingredients, if sold separately in such country, and B is the average invoice
price in such country of such other therapeutically active ingredients in the
combination, if sold separately in such country. If, in a specific country, such
other therapeutically active ingredients in the combination product are not sold
separately, Net Sales shall be adjusted by multiplying actual Net Sales of such
combination product in such country calculated pursuant to the first paragraph
of this Section 1.27 by the fraction A/C, where A is the average invoice price
in such country of the Product sold without such other active ingredients and C
is the invoice price in such country of such combination product. If, in a
specific country, a Product without such other active ingredients is not sold
separately, Net Sales shall be calculated by multiplying actual Net Sales of
such combination product in such country calculated pursuant to the first
paragraph of this Section 1.27 by the fraction (C-B)/C, where B is the average
invoice price in such country of such other therapeutically active ingredients
in the combination product and C is the invoice price in such country of the
combination product. The invoice price for the Product without such other active
ingredients and for such other therapeutically active ingredients shall be for a
quantity comparable to that used in such combination product and of the same
class, purity and potency. If, in a specific country, neither a Product without
such other active ingredients nor such other therapeutically active ingredients
in such combination product are sold separately, a market price for such Product
and such other therapeutically active ingredients shall be negotiated by the
parties in good faith based upon the

<PAGE>

costs, overhead and profit as are then incurred for such combination product and
all similar substances then being made and marketed by ZYCOS and having an
ascertainable market price.

            1.28 "PATENT COST"

shall mean the costs incurred by Cohesion in connection with the preparation,
filing, prosecution and maintenance of the Cohesion Patents.

            1.29 "PATENTS"

shall mean (a) all patents and patent applications, (b) any substitutions,
divisions, continuations, continuations-in-part, reissues, renewals,
registrations, confirmations, re-examinations, extensions, supplementary
protection certificates and the like, and any provisional applications, of any
such patents or patent application, and (c) any foreign or international
equivalent of any of the foregoing.

            1.30 "PERSON"

shall mean an individual, sole proprietorship, partnership, limited partnership,
limited liability partnership, corporation, limited liability company, business
trust, joint stock company, trust, unincorporated association, joint venture or
other similar entity or organization, including a government or political
subdivision, department or agency of a government.

            1.31 "PRODUCT"

shall mean a nucleic acid-based product (a) which contains Hydrogels and (b) the
manufacture, use or sale of which is covered by a Valid Claim in a Cohesion
Patent.

            1.32 "REGULATORY APPROVAL"

shall mean any and all approvals (including pricing and reimbursement
approvals), licenses, registrations or authorizations of any Regulatory
Authority, necessary for the Exploitation of the Licensed Technology in a
country in the Territory, including any (a) approval of any Products (including
any INDs, NDAs, and supplements and amendments thereto); (b) pre- and
post-approval marketing authorizations (including any prerequisite Manufacturing
approval or authorization related thereto); (c) labeling approval; and (d)
technical, medical and scientific licenses.

            1.33 "REGULATORY AUTHORITY"

shall mean any applicable supra-national, federal, national, regional, state,
provincial or local regulatory agencies, departments, bureaus, commissions,
councils or other government entities regulating or otherwise exercising
authority with respect to the Exploitation of the Licensed Technology in the
Territory.

<PAGE>

            1.34 "REGULATORY DOCUMENTATION"

shall mean all applications, registrations, licenses, authorizations and
approvals (including all Regulatory Approvals), all correspondence submitted to
or received from Regulatory Authorities (including minutes and official contact
reports relating to any communications with any Regulatory Authority) and all
supporting documents and all pre-clinical and clinical studies and tests,
relating to any Products , and all data contained in any of the foregoing,
including all INDs, NDAs, regulatory drug lists, advertising and promotion
documents, adverse event files, complaint files and Manufacturing records.

            1.35 "TERRITORY"

shall mean the entire world.

            1.36 "THIRD PARTY"

shall mean any Person other than ZYCOS, Cohesion and their respective
Affiliates.

            1.37 "TRADEMARK"

shall include any word, name, symbol, color, designation or device or any
combination thereof, including any trademark, trade dress, brand mark, trade
name, brand name, logo or business symbol.

            1.38 "VALID CLAIM"

shall mean, with respect to a particular country, a claim of an issued and
unexpired patent in such country that (a) has not been revoked or held
unenforceable or invalid by a decision of a court or governmental agency of
competent jurisdiction from which no appeal can be taken or has been taken
within the time allowed for appeal; and (b) has not been abandoned, disclaimed,
denied or admitted to be invalid or unenforceable through reissue or disclaimer
or otherwise in such country.

            1.39 "WRITTEN RECORDS"

shall have the meaning set forth in Section 1.27.

            1.40 "ZYCOS"

shall have the meaning set forth in the preamble of this Agreement.

            1.41 "ZYCOS INFORMATION"

shall have the meaning set forth in Section 7.1(c).

<PAGE>

            1.42 "ZYCOS INTELLECTUAL PROPERTY"

shall have the meaning set forth in Section 6.1(c).

            1.43 "ZYCOS TECHNOLOGY"

shall mean the ZYCOS Intellectual Property comprising Improvements to (a) the
Hydrogels and (b) the Method.

                                   ARTICLE II
                        DEVELOPMENT AND COMMERCIALIZATION

            2.1 DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES.

ZYCOS shall have the sole right to Exploit the Products in the Field in the
Territory. Except as otherwise expressly provided herein, ZYCOS shall be solely
responsible for all costs and expenses in connection with such development and
commercialization activities.

            2.2 PRODUCT DEVELOPMENT.

The parties acknowledge and agree that all decisions relating to ZYCOS's
Exploitation and pricing of any Products or any Improvements thereto covered
under this Agreement, including any decision not to develop or Exploit Products,
shall be within the sole discretion of ZYCOS. Cohesion acknowledges that ZYCOS
is in the business of researching, developing, manufacturing, marketing and
selling pharmaceutical products, and nothing in this Agreement shall be
construed as restricting such business or imposing on ZYCOS the duty to Exploit
or otherwise commercialize the Products or any Improvements thereto for which
royalties are payable hereunder to the exclusion of, or in preference to, any
other product, or in any way other than in accordance with its normal commercial
practices.

            2.3 INFORMATION DISCLOSURE.

Cohesion shall, without additional compensation, disclose and make available to
ZYCOS, in whatever form ZYCOS may reasonably request, all Cohesion Know-How and
all Information and Inventions covered or claimed by any Cohesion Patents, in
each case which are relevant to the Field, promptly after the Effective Date,
and thereafter promptly upon the earlier of the development, making, conception
or reduction to practice of such Cohesion Know-How or Information and
Inventions; provided, however, that ZYCOS shall compensate Cohesion for time
spent by Cohesion employees in making such disclosures, after the initial forty
(40) hours, the rate of which compensation shall be mutually determined in good
faith by the parties.

            2.4 RIGHTS AND OBLIGATIONS.

Any and all rights of ZYCOS under this Article II are intended, and shall be
construed, to benefit such of its Affiliates and sublicensees as and to the
extent ZYCOS may, from time to time,

<PAGE>

designate. Further, ZYCOS shall have the right to satisfy any or all of its
obligations under this Article II through one or more of its Affiliates or
sublicensees.

                                   ARTICLE III
                            LICENSE GRANTS AND SUPPLY

            3.1 GRANTS TO ZYCOS.

                  (a) License Grant. Subject to Section 3.1(b) and the other
terms and conditions of this Agreement, Cohesion hereby grants to ZYCOS and its
Affiliates a non-exclusive, perpetual, royalty-bearing license in the Territory,
with the right to grant sublicenses, under the Cohesion Patents and the Cohesion
Know-How to Manufacture Hydrogels and to Exploit the Products and any
Improvements thereto in the Field.

                  (b) Right of First Negotiation. Cohesion shall provide written
notice to ZYCOS pursuant to this Section 3.1(b) before entering into
negotiations with any Third Party for the grant by Cohesion to such Third Party
of an exclusive license in the Territory under the Cohesion Patents and the
Cohesion Know-How to Manufacture Hydrogels, or to Exploit the Products or any
Improvements thereto in the Field, and, in any event, before granting any such
exclusive license to any such Third Party. For a period of not less than ninety
(90 days following receipt by ZYCOS of such notice, Cohesion shall negotiate
exclusively with ZYCOS in good faith regarding the terms and conditions on which
Cohesion would be willing to grant such an exclusive license to ZYCOS, which
terms and conditions shall be commercially reasonable with respect to both
parties. If, at the conclusion of such good faith negotiations, Cohesion and
ZYCOS do not execute a definitive agreement providing for the grant by Cohesion
to ZYCOS of such exclusive rights, Cohesion shall have the right to negotiate
with one or more Third Parties with respect to the grant by ZYCOS to such party
or parties of such exclusive rights; provided, however, that Cohesion may not
grant such exclusive rights to any Third Party on terms that are more favorable
than the terms which Cohesion offered to ZYCOS. By way of example, and without
limitation of the foregoing, Cohesion shall not grant to any Third Party such
exclusive rights at royalty rates that are lower in amount than the royalty
rates that Cohesion offered to ZYCOS.

                  (c) Grant of Option. From time to time during the term of this
Agreement, ZYCOS shall have the right to initiate negotiations with Cohesion to
acquire an exclusive, perpetual, royalty-bearing license in the Territory, with
the right to grant sublicenses, under the Cohesion Patents and the Cohesion
Know-How to Exploit in the Field products (i) which are not nucleic-acid based
and (ii) (A) which contain Hydrogels and (B) the manufacture, use or sale of
which are covered by a Valid Claim of a Cohesion Patent. Cohesion shall conduct
such negotiations with ZYCOS in good faith.

            3.2 FUTURE GRANT TO COHESION.

On written request from Cohesion, ZYCOS agrees to grant to Cohesion a
non-exclusive, perpetual, royalty-bearing license in the Territory, with right
to grant sublicenses, under the ZYCOS Technology to Manufacture and Exploit
surgical sealants in the field of human tissue repair and regeneration, in
accordance with and subject to the terms and conditions of a separate

<PAGE>

written agreement to be negotiated in good faith between the parties. The
royalty rates that Cohesion shall pay to ZYCOS under any such license shall be
the same as those set forth in Section 4.1 with respect to the sales of Products
hereunder.

            3.3 RESERVATION OF RIGHTS.

Cohesion grants no rights to ZYCOS, its Affiliates, or its sublicensees in this
Agreement except as expressly provided herein.

            3.4 SUPPLY.

Cohesion agrees to supply ZYCOS with Hydrogels upon the written request of
ZYCOS, in accordance with and subject to the terms and conditions of a separate
written agreement to be negotiated by the parties, provided that Cohesion shall
have no such obligation unless the parties so agree in such separate written
agreement.

            3.5 RESEARCH.

Cohesion agrees to perform research on Hydrogels upon the written request of
ZYCOS, in accordance with and subject to the terms and conditions of a separate
written agreement to be negotiated in good faith between the parties; provided
that Cohesion shall have no such research obligation unless the parties so agree
in such separate written agreement. Such agreement shall provide an outline of
the work to be performed and a budget approved by both parties.

                                   ARTICLE IV
                             PAYMENTS AND ROYALTIES

            4.1 PAYMENTS TO COHESION.

In partial consideration of the licenses and other rights granted herein and
subject to the terms and conditions set forth in this Agreement, ZYCOS shall
make the following royalty payments to Cohesion:

                  (a) Royalties on Direct Sales. Subject to Section 4.5, ZYCOS
shall pay to Cohesion royalties equal to [Text Deleted] by ZYCOS or its
Affiliates of each Product in each country in the Territory in which there is a
Valid Claim under any issued Cohesion Patents that provide exclusive and
enforceable rights with respect to the sale of such Product in such country.

                  (b) Royalties on Indirect Sales. Subject to Section 4.5, with
respect to each Product developed and/or commercialized and/or sold by
sublicensees of ZYCOS, ZYCOS shall pay to Cohesion a royalty equal to [Text
Deleted]

<PAGE>

            4.2 ROYALTY TERM.

ZYCOS's royalty obligations under Section 4.1 shall terminate, on a
country-by-country basis, with respect to each Product, upon the expiration date
in a country of the last to expire of any issued Cohesion Patent that includes
at least one Valid Claim covering the sale of such Product in such country. Upon
termination of the royalty obligations of ZYCOS under this Section 4.2 in a
country, the license grants to ZYCOS in Section 3.1 shall become fully paid-up
with respect to such country and Net Sales and other payments with respect to
Products in such country shall be excluded from the royalty calculations set
forth in Section 4.1.

            4.3 ROYALTY PAYMENTS.

Running royalties shall be payable with respect to a Product in a country on a
quarterly basis, within sixty (60) days after the end of each Calendar Quarter,
based upon the Net Sales during such Calendar Quarter, commencing with the
Calendar Quarter in which the first sale for use or consumption by the general
public of such Product in such country after Regulatory Approval (including
pricing and reimbursement approval) for the marketing and sale of such Product
has been obtained in such country. Royalties shall be calculated in accordance
with U.S. generally accepted accounting principles consistently applied and with
the terms of this Article IV. Only one royalty payment will be due on Net Sales
even though the Exploitation of a Product may be covered by more than one
Cohesion Patent in a country.

            4.4 ROYALTY STATEMENTS.

Each royalty payment hereunder shall be accompanied by a statement showing (a)
Net Sales by ZYCOS and its Affiliates and the gross amount invoiced with respect
thereto on a country-by-country basis, (b) the number of units of Product sold
by ZYCOS or its Affiliates on a country-by-country basis during the applicable
Calendar Quarter, (c) the amount of royalties due on such Net Sales, (d) any
amounts received by ZYCOS or its Affiliates on which royalties are due to
Cohesion pursuant to Section 4.1(b), and (e) the amount of royalties due to
Cohesion pursuant to Section 4.1(b).

            4.5 REDUCTION OF ROYALTY.

                  (a) Compulsory Licenses.

In the event that a court or a governmental agency of competent jurisdiction
requires ZYCOS or a ZYCOS Affiliate or sublicensee to grant a compulsory license
to a Third Party permitting such Third Party to make and sell a Product in a
country, then the royalty rate to be paid by ZYCOS pursuant to Section 4.1(b)
with respect to amounts received from such sublicensee shall automatically be
reduced to the lesser of (i) the rate provided in Section 4.1(b), and (ii) fifty
percent (50%) of the royalty rate under such compulsory license, during the time
period when such compulsory license is in effect and being exercised; provided,
however, that if such country is in the European Union, such reduction shall
apply to all other member countries of the European Union.

                  (b) Stacking Clause.

<PAGE>

                        (i) For Products sold by ZYCOS or its Affiliates to
Third Parties, where the sum of royalty payments owed by ZYCOS and its
Affiliates to Cohesion and to any Third Parties exceeds [Text Deleted] for a
given Product for a Calendar Quarter, the royalty rate under Section 4.l(a)
shall be reduced pro rata such that the aggregate royalty rate payable on such
Product does not exceed [Text Deleted].

                        (ii) In the case of a Product developed and/or
commercialized by a sublicensee of ZYCOS, where ZYCOS is legally required to
make payment to one or more Third Parties in order that such sublicensee may
develop and/or commercialize such Product, then if the sum of royalty payments
owed by ZYCOS and its Affiliates to Cohesion and to any such Third Parties [Text
Deleted] of all amounts received by ZYCOS from such sublicensee that are subject
to the royalty obligations of ZYCOS under Section 4.1(b) with respect to a
Calendar Quarter, the royalty rate under Section 4.1(b) shall be reduced pro
rata such that the aggregate amount payable by ZYCOS with respect to such
Product for such Calendar Quarter does not exceed [Text Deleted].

            4.6 RECORDS RETENTION; AUDIT.

                  (a) Record Retention. Until the third (3rd) anniversary of
December 31 of the Calendar Year in which a Product is sold by ZYCOS or an
Affiliate or sublicensee of ZYCOS, ZYCOS shall, and shall ensure that its
Affiliates and sublicensees shall, keep records of such sales in sufficient
detail to confirm the accuracy of the royalty calculations hereunder.

                  (b) Audit. Upon the written request of Cohesion and not more
than once in a Calendar Year, ZYCOS shall, and shall cause its Affiliates to,
permit an independent certified public accounting firm of nationally recognized
standing selected by Cohesion, and reasonably acceptable to ZYCOS, at Cohesion'
expense, to have access during normal business hours, and upon reasonable prior
written notice, to such of the records of ZYCOS or its Affiliates or
sublicensees as may be reasonably necessary to verify the accuracy of the
royalty reports hereunder, as well as the Written Records, for any Calendar Year
ending not more than thirty-six (36) months prior to the date of such request.
The accounting firm shall disclose to Cohesion and ZYCOS whether such royalty
reports and Written Records are correct or incorrect and the specific details
concerning any discrepancies. No other information shall be provided to
Cohesion. Any failure by Cohesion to exercise its right under this Section
4.6(b) with respect to a Calendar Year within the time period allotted therefor,
shall constitute a waiver by Cohesion of its right to later object to any
payments made by ZYCOS under this Agreement during such Calendar Year, except
where ZYCOS has willfully and wrongfully withheld payments.

                  (c) Confidentiality. Cohesion shall treat all information
subject to review under this Section 4.6 in accordance with the confidentiality
provisions of Article VII and shall cause its accounting firm to enter into a
reasonably acceptable confidentiality agreement with ZYCOS obligating such firm
to retain all such financial information in confidence pursuant to such
confidentiality agreement.

<PAGE>

            4.7 MODE OF PAYMENT.

All payments to Cohesion under this Agreement shall be made by deposit of United
States Dollars in the requisite amount to such bank account as Cohesion may from
time to time designate by notice to ZYCOS. ZYCOS shall pay, for the account of
Cohesion, all withholding, sales, value-added and other taxes, which amounts
shall be deducted by ZYCOS from the amounts owed to Cohesion under this
Agreement. With respect to sales outside the United States, royalty payments
shall be calculated in the currency of the country where such sales occurred
and, after such calculation, be converted into United States Dollars utilizing
currency exchange rates for the last Calendar Quarter for which remittance is
made. For each month and each currency, such exchange rate shall equal the
arithmetic average of the daily exchange rates (obtained as described below)
during the Calendar Quarter; each such daily exchange rate shall be obtained
from the Reuters Daily Rate Report or The Wall Street Journal, Eastern U.S.
Edition, or, if not so available, as otherwise agreed by the parties.

                                    ARTICLE V
                              ADVERSE EVENT REPORTS

            Cohesion shall provide ZYCOS with all information necessary or
desirable for ZYCOS to comply with all Applicable Law with respect to the Method
and Products, as the case may be. In furtherance thereof, Cohesion shall (a)
develop appropriate adverse experience reporting procedures; (b) provide to
ZYCOS any material information on the Method and Products from preclinical or
clinical laboratory, animal toxicology and pharmacology studies, as well as
serious or unexpected adverse experience reports from clinical trials and
commercial experiences with the Method and Products; and (c) report and provide
such information to ZYCOS in such a manner and time so as to enable ZYCOS to
comply with all Applicable Law in countries for which Regulatory Approval is or
will be sought.

                                   ARTICLE VI
                          INTELLECTUAL PROPERTY RIGHTS

            6.1 INTELLECTUAL PROPERTY OWNERSHIP.

                  (a) Ownership of ZYCOS Intellectual Property, Regulatory
Documentation, and Trademarks. As between the parties, ZYCOS shall own and
retain all rights, title and interest in and to any and all ZYCOS Intellectual
Property, Regulatory Documentation generated by or on behalf of ZYCOS, its
Affiliates or sublicensees, and Trademarks used by or on behalf of ZYCOS, its
Affiliates or sublicensees in connection with the Products.

                  (b) Ownership of Licensed Technology. Subject to the license
grants to ZYCOS under Section 3.1, as between the parties, Cohesion shall own
and retain all rights, title and interest in and to all Licensed Technology.

<PAGE>

                  (c) Ownership of New Information and Inventions. Cohesion
acknowledges and agrees that, in the course of conducting their respective
businesses, including developing and commercializing Products, ZYCOS and its
Affiliates may now or in the future discover or develop Information and
Inventions relating to the diagnosis, treatment or prevention of any disease,
disorder or condition in humans, including any Products. ZYCOS and its
Affiliates, as applicable, shall own all right, title and interest in and to any
such Information and Inventions, including any Improvements made by or on behalf
of ZYCOS or any of its Affiliates to the Method, the Hydrogels, the Products, or
any process for Manufacturing the Hydrogels, the Products, and any Improvements
to the foregoing or any intermediate thereof, including any device for the
administration of the Products and any Improvements to the foregoing (the "ZYCOS
Intellectual Property").

            6.2 PROSECUTION OF PATENTS.

                  (a) Patents. Cohesion shall be responsible for obtaining,
prosecuting and maintaining the Cohesion Patents in the Territory and for all
Patent Costs.

                  (b) Cooperation.

Cohesion shall regularly provide ZYCOS with copies of all patent applications
filed hereunder and other material submissions and correspondence with any
patent authorities, as applicable, in sufficient time, but in any event not less
than thirty (30) days prior to the date a reply is required by the relevant
patent authorities, to allow for review and comment by ZYCOS. In addition,
Cohesion shall provide ZYCOS and its counsel with an opportunity to consult with
Cohesion and its counsel regarding the filing and contents of any application,
amendment, registration, submission, response or correspondence with any patent
authorities (provided that ZYCOS shall pay the reasonable costs of such
consultation), and Cohesion shall accede to reasonable requests of ZYCOS
regarding the filing and prosecution of the Cohesion Patents; provided, however,
that ZYCOS shall have the sole right to approve in advance any material with
respect to a patent application or to any other material filed with the patent
authorities in the Territory that relates, directly or indirectly, to the Field.
Any disagreement between the parties relating to any such material shall be
subject to arbitration pursuant to Section 11.6.

                  (c) ZYCOS Intellectual Property.

ZYCOS shall have the sole right, at its cost and expense, to obtain, prosecute
and maintain any intellectual property protection for any ZYCOS Intellectual
Property and for any Trademark (excluding any Trademarks owned by Cohesion) with
respect to the Products.

                  (d) Election not to Prosecute.

If Cohesion elects not (i) to pursue the filing, prosecution or maintenance of a
Cohesion Patent in a particular country, or (ii) to take any other action with
respect to a Cohesion Patent in a particular country that is necessary or useful
to establish or preserve rights thereto, then, in either case, Cohesion shall so
notify ZYCOS promptly in writing and in good time to enable ZYCOS to meet any
deadlines by which an action must be taken to establish or preserve any such
rights in such Cohesion Patent in such country. Upon receipt of any such notice
by Cohesion or if, at any

<PAGE>

time, Cohesion fails to initiate any such action within thirty (30) days after a
request by ZYCOS that it do so (and thereafter diligently pursue such action),
ZYCOS shall have the right, but not the obligation, to pursue the filing or
registration, or support the continued prosecution or maintenance, of such
Cohesion Patent at its expense in such country. If ZYCOS elects to pursue such
filing or registration, as the case may be, or continue such support, then ZYCOS
shall notify Cohesion of such election and Cohesion shall, and shall cause its
Affiliates to (i) reasonably cooperate with ZYCOS in this regard, and (ii)
promptly grant to ZYCOS, without additional consideration, an exclusive,
perpetual, irrevocable, royalty-free license in the Territory under such
Cohesion Patent, as applicable, in such country.

            6.3 ENFORCEMENT OF PATENTS.

ZYCOS shall have the right, at its expense, to seek to remove any infringement
of the Cohesion Patents to the extent that such infringement relates to the
development and commercialization of Products in the Field (or Improvements
thereto) in the Territory. ZYCOS shall retain any amounts recovered, whether by
settlement or judgment, pursuant to actions taken under this Section. Cohesion
shall, at its own expense, provide reasonable assistance to ZYCOS with respect
to the foregoing, including providing access to relevant documents and other
evidence, making its employees available at reasonable business hours, and
joining the action to the extent necessary to allow ZYCOS to maintain the
action. Except as otherwise provided by the first sentence of this Section, each
party shall retain the sole right to enforce its rights under any Patents and to
any Trademarks against all infringers at its sole cost and expense.

            6.4 INFRINGEMENT OF THIRD PARTY RIGHTS.

                  (a) Third Party Licenses. If (i) in the opinion of ZYCOS, one
or more Patents with respect to the Licensed Technology have issued to a Third
Party in any country such that ZYCOS cannot Exploit the Licensed Technology in
such country without infringing such Patent or (ii) as a result of any claim
made against ZYCOS or any of its Affiliates or sublicensees alleging that the
Exploitation of the Licensed Technology by ZYCOS, its Affiliates or any of its
sublicensees infringes or misappropriates any Patent or any other intellectual
property right of a Third Party in any country, a judgment is entered by a court
of competent jurisdiction from which no appeal is taken within the time
permitted for appeal, such that ZYCOS cannot Exploit the Licensed Technology in
such country without infringing the Patent or other proprietary rights of such
Third Party, then, in either case, ZYCOS shall have the first right, but not the
obligation, to negotiate and obtain a license from such Third Party as necessary
for ZYCOS and its Affiliates and sublicensees to Exploit the Licensed Technology
in such country. Any amounts paid by ZYCOS as royalties under such licenses
shall be creditable against royalty amounts payable by ZYCOS to Cohesion under
Article IV of this Agreement, provided that such royalty payments shall not be
reduced below [Text Deleted].

                  (b) Third Party Litigation. In the event that a Third Party
institutes a patent, trade secret, or other infringement suit against ZYCOS or
its Affiliates or sublicensees during the term of this Agreement, alleging that
the Exploitation of the Licensed Technology infringes one or more patent, trade
secret or other intellectual property rights held by such Third Party, then
ZYCOS, at its cost and expense, shall assume direction and control of the
defense of claims arising therefrom (including the right to settle such claims
at its sole discretion). The

<PAGE>

reasonable costs and expenses and any damage awards or other payments or
penalties incurred by ZYCOS in connection therewith (other than prospective
royalties which shall be governed by Section 6.4(a)) that are not offset by
proceeds therefrom shall be creditable against royalty amounts payable by ZYCOS
to Cohesion under Article IV of this Agreement, provided that such royalty
payments not be reduced [Text Deleted]

                  (c) Cooperation. In the event that a Third Party institutes a
Patent, trade secret or other infringement suit against ZYCOS, or its Affiliates
or sublicensees during the term of this Agreement (with respect to the
Exploitation of the Licensed Technology), Cohesion shall, and shall cause its
Affiliates to, use all reasonable efforts to assist and cooperate with ZYCOS in
connection with the defense of such suit.

                  (d) Retained Rights. Nothing in this Section 6.4 shall prevent
either party, at its own expense, from obtaining any license or other rights
from Third Parties it deems appropriate in order to permit the full and
unhindered exercise of its rights under this Agreement.

                                   ARTICLE VII
                        CONFIDENTIALITY AND NONDISCLOSURE

            7.1 CONFIDENTIAL INFORMATION.

                  (a) Defined. "Confidential Information" means (i) where
Cohesion is the receiving party, any information relating to the terms of this
Agreement, any proposed or actual Exploitation of a Product or a Hydrogel (or
any Improvements to a Product or a Hydrogel) by ZYCOS, its Affiliates or
sublicensees, the Regulatory Documentation, and all development, sales and
marketing plans for the Products or any Improvements to the foregoing, or to the
business affairs or other activities of ZYCOS, and (ii) where ZYCOS is the
receiving party, any information marked as confidential, or, if disclosed
orally, identified as confidential at the time of disclosure and confirmed in
writing within five (5) business days of such disclosure by Cohesion, or
relating to the terms of this Agreement, but not including any ZYCOS
Information.

                  (b) Exclusions. Notwithstanding the foregoing, Confidential
Information shall not include any information that:

                        (i) is or hereafter becomes part of the public domain by
public use, publication, general knowledge or the like through no wrongful act,
fault or negligence on the part of receiving party;

                        (ii) can be demonstrated by documentation or other
competent proof to have been in the receiving party's possession prior to
disclosure by the disclosing party;

                        (iii) is subsequently received by the receiving party
from a Third Party who is not bound by any obligation of confidentiality with
respect to said information;

                        (iv) is generally made available to Third Parties by
disclosing party without restriction on disclosure; or

<PAGE>

                        (v) is independently developed by or for the receiving
party without reference to the disclosing party's Confidential Information.

Further, any combination of Confidential Information shall not be considered in
the public domain or in the possession of the receiving party merely because
individual elements of such Confidential Information are in the public domain or
in the possession of the receiving party unless the combination and its
principles are in the public domain or in the possession of the receiving party.

                  (c) Cohesion Obligations. Cohesion recognizes that by reason
of ZYCOS's status as an exclusive licensee pursuant to the grant under Section
3.1, ZYCOS has an interest in Cohesion' retention in confidence of certain
information of Cohesion. Accordingly, Cohesion shall, and shall cause its
officers, directors, employees and agents to, keep completely confidential, and
not publish or otherwise disclose, and not use directly or indirectly for any
purposes, any information relating directly to the Licensed Technology, the
Regulatory Documentation, including the Regulatory Approvals, or the
development, sales or marketing of any Products (or any Improvements thereto) in
the Field (the "ZYCOS Information"), except to the extent (i) the ZYCOS
Information is in the public domain through no fault of Cohesion, its Affiliates
or any of their respective officers, directors, employees and agents, (ii) such
disclosure or use would be permitted under Section 7.3 or 7.4, (iii) such
disclosure or use is otherwise expressly permitted by the terms of this
Agreement or is reasonably necessary for the performance of this Agreement, or
(iv) the disclosure is of Cohesion Know-How to other licensees thereof. For
clarification, the disclosure by Cohesion to ZYCOS or by ZYCOS to Cohesion of
ZYCOS Information shall not cause such information to cease to be subject to the
confidentiality provisions of this Section 7.1(c).

            7.2 CONFIDENTIALITY OBLIGATIONS.

At all times during the term of this Agreement and for a period of five (5)
years following termination or expiration hereof, each party shall, and shall
cause its officers, directors, employees and agents to, keep completely
confidential and not publish or otherwise disclose and not use, directly or
indirectly, for any purpose, any Confidential Information furnished to it by the
other party, except to the extent such disclosure or use is expressly permitted
by the terms of this Agreement or is reasonably necessary for the performance of
this Agreement.

            7.3 PERMITTED DISCLOSURES.

Each party may disclose Confidential Information to the extent that such
disclosure is:

                  (a) Made in response to a valid order of a court of competent
jurisdiction or other supra-national, federal, national, regional, state,
provincial and local governmental or regulatory body of competent jurisdiction;
provided, however, that the receiving party shall first have given notice to the
disclosing party and given the disclosing party a reasonable opportunity to
quash such order and to obtain a protective order requiring that the
Confidential Information and documents that are the subject of such order be
held in confidence by such court or agency or, if disclosed, be used only for
the purposes for which the order was issued; and provided further that if a
disclosure order is not quashed or a protective order is not

<PAGE>

obtained, the Confidential Information disclosed in response to such court or
governmental order shall be limited to that information which is legally
required to be disclosed in response to such court or governmental order;

                  (b) Otherwise required by law, in the opinion of legal counsel
to the receiving party as expressed in an opinion letter in form and substance
reasonably satisfactory to the disclosing party, which shall be provided to the
disclosing party at least two (2) business days prior to the receiving party's
disclosure of the Confidential Information pursuant to this Section 7.3(b);

                  (c) Made by the receiving party to the Regulatory Authorities
as required in connection with any filing, application or request for Regulatory
Approval; provided, however, that reasonable measures shall be taken to assure
confidential treatment of such information; or

                  (d) Made by ZYCOS or its Affiliates or sublicensees to Third
Parties as may be necessary or useful in connection with the Exploitation of the
Products as contemplated by this Agreement, including subcontracting and
sublicensing transactions in connection therewith.

            7.4 PUBLICATIONS.

At least forty-five (45) days prior to the submission for publication or other
public disclosure by Cohesion, or any of its officers, directors, employees, or
agents, of any information, data or results pertaining to or resulting from the
Cohesion Patents or the Cohesion Know-How and relevant to the Field, Cohesion
shall provide a copy of such proposed publication or a summary of such proposed
disclosure to ZYCOS. Upon the written request of ZYCOS, which shall be received
by Cohesion not later than forty-five (45) days after the receipt by ZYCOS of
such copy or summary, Cohesion agrees (i) to delete from the proposed submission
or disclosure any ZYCOS Information therein which ZYCOS requests be deleted,
and/or (ii) to defer, for a period not to exceed sixty (60) days from the date
of ZYCOS' request, the proposed submission or disclosure until Cohesion has
received notice from ZYCOS that ZYCOS has filed a patent application covering
subject matter disclosed in the proposed publication or disclosure, as ZYCOS in
its sole discretion may elect. Cohesion agrees to acknowledge ZYCOS in all such
publications or other public disclosures by coauthorship or acknowledgement, as
appropriate according to customary practice for academic research publications
and disclosures.

            7.5 USE OF NAME.

Neither party shall mention or otherwise use the name, insignia, symbol,
trademark, trade name or logotype of the other party (or any abbreviation or
adaptation thereof) in any publication, press release, promotional material or
other form of publicity without the prior written approval of such other party
in each instance, which shall not be unreasonably withheld. The restrictions
imposed by this Section shall not prohibit either party from making any
disclosure identifying the other party that is required by law. Notwithstanding
the foregoing, ZYCOS may (a) refer to publications by employees of Cohesion in
the scientific literature and (b) state that a license from Cohesion has been
granted as herein provided.

<PAGE>

            7.6 PRESS RELEASES.

Press releases or other similar public communication by either party relating to
this Agreement shall be approved in advance by the other party, which approval
shall not be unreasonably withheld or delayed, except for those communications
required by securities or other Applicable Law, disclosures of information for
which written consent has previously been obtained, information that has been
previously disclosed publicly or as otherwise set forth in this Agreement.

                                  ARTICLE VIII
                              TERM AND TERMINATION

            8.1 TERM.

This Agreement shall commence upon the Effective Date and shall continue in full
force and effect, unless earlier terminated in accordance with this Article
VIII, on a country-by-country basis until the expiration date of the last to
expire of any issued Cohesion Patent that includes at least one Valid Claim
covering the sale of a Product in such country.

            8.2 TERMINATION FOR MATERIAL BREACH.

Failure by a party to comply with any of its material obligations contained
herein, including the failure of ZYCOS to pay royalties in accordance with
Article IV hereof, shall entitle the party not in default to give to the party
in default notice specifying the nature of the default, requiring the defaulting
party to make good or otherwise cure such default, and stating its intention to
terminate if such default is not cured. If such default is not cured within
thirty (30) days (the "Cure Period") after the receipt of such notice (or, if
such default cannot be cured within such thirty (30)-day period, if the party in
default does not commence actions to cure such default within the Cure Period
and thereafter diligently continue such actions), the party not in default shall
be entitled, without prejudice to any of its other rights conferred on it by
this Agreement, and in addition to any other remedies available to it by law or
in equity, to terminate this Agreement in its entirety; provided, however, that
any right to terminate under this Section 8.2 shall be stayed in the event that,
during any Cure Period, the party alleged to have been in default shall have
initiated dispute resolution in accordance with Section 11.6(a) with respect to
the alleged default, which stay shall last so long as the initiating party
diligently and in good faith cooperates in the prompt resolution of such dispute
resolution proceedings.

            8.3 TERMINATION BY ZYCOS.

ZYCOS shall have the right in its sole discretion to terminate this Agreement in
its entirety upon thirty (30) days' prior written notice to Cohesion.

            8.4 TERMINATION UPON INSOLVENCY.

Either party may terminate this Agreement if, at any time, the other party shall
file in any court or agency pursuant to any statute or regulation of any state,
country or jurisdiction, a petition in

<PAGE>

bankruptcy or insolvency or for reorganization or for an arrangement or for the
appointment of a receiver or trustee of that party or of its assets, or if the
other party proposes a written agreement of composition or extension of its
debts, or if the other party shall be served with an involuntary petition
against it, filed in any insolvency proceeding, and such petition shall not be
dismissed within sixty (60) days after the filing thereof, or if the other party
shall propose or be a party to any dissolution or liquidation, or if the other
party shall make an assignment for the benefit of its creditors.

            8.5 CONSEQUENCES OF TERMINATION.

                  (a) Return of Material; Termination of Rights.

                        (i) Upon termination of this Agreement by ZYCOS pursuant
to Section 8.3 or Cohesion pursuant to Section 8.2 or 8.4, each party, at the
request of the other, shall return all data, files, records and other materials
in its possession or control relating to the Method, the Hydrogels, or the
Products, as applicable, and containing or comprising the other party's
Information and Inventions or other Confidential Information (including the
ZYCOS Information, as applicable), to which the returning party does not retain
rights hereunder. In the event of termination by ZYCOS pursuant to Section 8.3,
all licenses and other rights granted by Cohesion under Article III shall
terminate. In the event of termination by Cohesion pursuant to Section 8.2 or
8.4, all such licenses and rights, and all related payment obligations of ZYCOS
pursuant to Article IV, shall survive such termination in accordance with their
terms.

                        (ii) Upon termination of this Agreement by ZYCOS
pursuant to Section 8.2 or 8.4, (A) Cohesion shall return all data, files,
records and other materials in its possession or control containing or
comprising ZYCOS's Information and Inventions or other Confidential Information
(including the ZYCOS Information, as applicable); and (B) all licenses and other
rights granted by Cohesion under Article III, and all related payment
obligations of ZYCOS pursuant to Article IV, shall survive such termination in
accordance with their terms.

                  (b) Rights Cumulative. The rights and remedies in Section
8.5(a) shall be cumulative and in addition to any other rights or remedies that
may be available to the parties.

            8.6 ACCRUED RIGHTS; SURVIVING OBLIGATIONS.

                  (a) Accrued Rights. Termination or expiration of this
Agreement for any reason shall be without prejudice to any rights that shall
have accrued to the benefit of a party prior to such termination or expiration.
Such termination or expiration shall not relieve a party from obligations that
are expressly indicated to survive the termination or expiration of this
Agreement.

                  (b) Survival. Without limiting the foregoing, Sections 3.3,
4.6, 6.1, 8.5, 11.4, 11.5, 11.6, 11.9, this Section 8.6, and Articles V, VII and
IX of this Agreement (and Sections 6.2, 6.3, and 6.4, to the extent that the
license grants in Article III survive pursuant to Section 8.5) shall survive the
termination or expiration of this Agreement for any reason.

<PAGE>

            8.7 RIGHTS IN BANKRUPTCY.

All rights and licenses granted under or pursuant to this Agreement by Cohesion
are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the
U.S. Bankruptcy Code, licenses of right to "intellectual property" as defined
under Section 101 of the U.S. Bankruptcy Code. The parties agree that ZYCOS, as
licensee of such rights under this Agreement, shall retain and may fully
exercise all of its rights and elections under the U.S. Bankruptcy Code. The
parties further agree that, in the event of the commencement of a bankruptcy
proceeding by or against Cohesion under the U.S. Bankruptcy Code, ZYCOS shall be
entitled to a complete duplicate of (or complete access to, as appropriate) any
such intellectual property and all embodiments of such intellectual property,
which, if not already in ZYCOS's possession, shall be promptly delivered to it
(a) upon any such commencement of a bankruptcy proceeding upon ZYCOS's written
request therefor, unless Cohesion elects to continue to perform all of its
obligations under this Agreement or (b) if not delivered under (a) above,
following the rejection of this Agreement by or on behalf of Cohesion upon
written request therefor by ZYCOS.

                                   ARTICLE IX
                                    INDEMNITY

            9.1 INDEMNIFICATION OF ZYCOS.

Cohesion shall indemnify ZYCOS, its Affiliates and their respective directors,
officers, employees and agents, and defend and save each of them harmless, from
and against any and all losses, damages, liabilities, costs and expenses
(including reasonable attorneys' fees and expenses) in connection with any and
all suits, investigations, claims or demands of Third Parties (collectively,
"Losses") arising from or occurring as a result of the breach by Cohesion of
this Agreement, except for those Losses for which ZYCOS has an obligation to
indemnify Cohesion pursuant to Section 9.2, as to which Losses each party shall
indemnify the other to the extent of their respective liability for the Losses;
provided, however, that Cohesion shall not be obligated to indemnify ZYCOS for
any Losses that arise as a result of gross negligence or willful misconduct on
the part of ZYCOS or any of its Affiliates.

            9.2 INDEMNIFICATION OF COHESION.

ZYCOS shall indemnify Cohesion, its Affiliates and their respective directors,
officers, employees and agents, and defend and save each of them harmless, from
and against any and all Losses arising from or occurring as a result of the
marketing, sale or use of any Product, except for those Losses for which
Cohesion has an obligation to indemnify ZYCOS and its Affiliates pursuant to
Section 9.1, as to which Losses each party shall indemnify the other to the
extent of their respective liability for the Losses; provided, however, that
ZYCOS shall not be obligated to indemnify Cohesion for any Losses that arise as
a result of gross negligence or willful misconduct on the part of Cohesion or
any of its Affiliates.

<PAGE>

            9.3 INDEMNIFICATION PROCEDURE.

                  (a) Notice of Claim. The indemnified party shall give the
indemnifying party prompt written notice (an "Indemnification Claim Notice") of
any Losses or discovery of fact upon which such indemnified party intends to
base a request for indemnification under Section 9.1 or Section 9.2, but in no
event shall the indemnifying party be liable for any Losses that result from any
delay in providing such notice. Each Indemnification Claim Notice must contain a
description of the claim and the nature and amount of such Loss (to the extent
that the nature and amount of such Loss is known at such time). The indemnified
party shall furnish promptly to the indemnifying party copies of all papers and
official documents received in respect of any Losses. All indemnification claims
in respect of a party, its Affiliates or their respective directors, officers,
employees and agents shall be made solely by such party to this Agreement (the
"Indemnified Party").

                  (b) Third Party Claims. The obligations of an indemnifying
party under this Article IX with respect to Losses arising from claims of any
Third Party that are subject to indemnification as provided for in Sections 9.1
or 9.2 (a "Third Party Claim") shall be governed by and be contingent upon the
following additional terms and conditions:

                        (i) Control of Defense. At its option, the indemnifying
party may assume the defense of any Third Party Claim by giving written notice
to the Indemnified Party within thirty (30) days after the indemnifying party's
receipt of an Indemnification Claim Notice. The assumption of the defense of a
Third Party Claim by the indemnifying party shall not be construed as an
acknowledgment that the indemnifying party is liable to indemnify any
indemnified party in respect of the Third Party Claim, nor shall it constitute a
waiver by the indemnifying party of any defenses it may assert against any
indemnified party's claim for indemnification. Upon assuming the defense of a
Third Party Claim, the indemnifying party may appoint as lead counsel in the
defense of the Third Party Claim any legal counsel selected by the indemnifying
party. In the event the indemnifying party assumes the defense of a Third Party
Claim, the Indemnified Party shall immediately deliver to the indemnifying party
all original notices and documents (including court papers) received by any
indemnified party in connection with the Third Party Claim. Should the
indemnifying party assume the defense of a Third Party Claim, the indemnifying
party shall not be liable to the Indemnified Party or any other indemnified
party for any legal expenses subsequently incurred by such indemnified party in
connection with the analysis, defense or settlement of the Third Party Claim
(except for any such expenses incurred with the prior written approval of the
indemnifying party). In the event that it is ultimately determined that an
indemnifying party is not obligated to indemnify, defend or hold harmless any
indemnified party from and against the Third Party Claim, the Indemnified Party
shall reimburse the indemnifying party for any and all costs and expenses
(including attorneys' fees and costs of suit) and any Losses incurred by the
indemnifying party in its defense of the Third Party Claim.

                        (ii) Right to Participate in Defense. Without limiting
Section 9.3(b)(i), any Indemnified Party shall be entitled to participate in,
but not control, the defense of such Third Party Claim and to employ counsel of
its choice for such purpose; provided, however, that such employment shall be at
the Indemnified Party's own expense unless (A) the employment thereof has been
specifically authorized by the indemnifying party in writing or (B)

<PAGE>

the indemnifying party has failed to assume the defense and employ counsel in
accordance with Section 9.3(b)(i) (in which case the Indemnified Party shall
control the defense).

                        (iii) Settlement. With respect to any Losses relating
solely to the payment of money damages in connection with a Third Party Claim
and that will not result in the Indemnified Party's becoming subject to
injunctive or other relief or otherwise adversely affecting the business of the
Indemnified Party in any manner, and as to which the indemnifying party shall
have acknowledged in writing the obligation to indemnify the Indemnified Party
hereunder, the indemnifying party shall have the sole right to consent to the
entry of any judgment, enter into any settlement or otherwise dispose of such
Loss, on such terms as the indemnifying party, in its sole discretion, shall
deem appropriate. With respect to all other Losses in connection with Third
Party Claims, where the indemnifying party has assumed the defense of the Third
Party Claim in accordance with Section 9.3(b)(i), the indemnifying party shall
have authority to consent to the entry of any judgment, enter into any
settlement or otherwise dispose of such Loss provided it obtains the prior
written consent of the Indemnified Party (which consent shall not be
unreasonably withheld or delayed). The indemnifying party shall not be liable
for any settlement or other disposition of a Loss by an Indemnified Party that
is reached without the written consent of the indemnifying party. Regardless of
whether the indemnifying party chooses to defend or prosecute any Third Party
Claim, no Indemnified Party shall admit any liability with respect to, or
settle, compromise or discharge, any Third Party Claim without the prior written
consent of the indemnifying party.

                        (iv) Cooperation. Regardless of whether the indemnifying
party chooses to defend or prosecute any Third Party Claim, the Indemnified
Party shall, and shall cause each other indemnified party to, cooperate in the
defense or prosecution thereof and shall furnish such records, information and
testimony, provide such witnesses and attend such conferences, discovery
proceedings, hearings, trials and appeals as may be reasonably requested in
connection therewith. Such cooperation shall include access during normal
business hours afforded to indemnifying party to, and reasonable retention by
the Indemnified Party of, records and information that are reasonably relevant
to such Third Party Claim, and making indemnified parties and other employees
and agents available on a mutually convenient basis to provide additional
information and explanation of any material provided hereunder, and the
indemnifying party shall reimburse the Indemnified Party for all its reasonable
out-of-pocket expenses in connection therewith.

                        (v) Expenses. Except as provided above, the reasonable
costs and expenses, including reasonable fees and disbursements of counsel,
incurred by the Indemnified Party in connection with any claim shall be
reimbursed on a Calendar Quarter basis by the indemnifying party, without
prejudice to the indemnifying party's right to contest the Indemnified Party's
right to indemnification and subject to refund in the event the indemnifying
party is ultimately held not to be obligated to indemnify the Indemnified Party.

<PAGE>

                                    ARTICLE X
                    REPRESENTATIONS, WARRANTIES AND COVENANTS

            10.1 REPRESENTATIONS, WARRANTIES AND COVENANTS.

Each party hereby represents, warrants and covenants to the other party as of
the Effective Date as follows:

                  (a) Such party (i) has the power and authority and the legal
right to enter into this Agreement and perform its obligations hereunder, and
(ii) has taken all necessary action on its part required to authorize the
execution and delivery of this Agreement and the performance of its obligations
hereunder. The Agreement has been duly executed and delivered on behalf of such
party and constitutes a legal, valid and binding obligation of such party and is
enforceable against it in accordance with its terms subject to the effects of
bankruptcy, insolvency or other laws of general application affecting the
enforcement of creditor rights and judicial principles affecting the
availability of specific performance and general principles of equity, whether
enforceability is considered a proceeding at law or equity.

                  (b) Such party is not aware of any pending or threatened
litigation (and has not received any communication) that alleges that such
party's activities related to this Agreement have violated, or that by
conducting the activities as contemplated herein such party would violate, any
of the intellectual property rights of any other Person.

                  (c) All necessary consents, approvals and authorizations of
all regulatory and governmental authorities and other Persons required to be
obtained by such party in connection with the execution and delivery of this
Agreement and the performance of its obligations hereunder have been obtained.

                  (d) The execution and delivery of this Agreement and the
performance of such party's obligations hereunder (i) do not conflict with or
violate any requirement of applicable law or regulation or any provision of
articles of incorporation, bylaws or limited partnership agreement of such
party, as applicable, in any material way, and (ii) do not conflict with,
violate, or breach or constitute a default or require any consent under, any
contractual obligation or court or administrative order by which such party is
bound.

            10.2 ADDITIONAL REPRESENTATIONS, WARRANTIES AND COVENANTS OF ZYCOS.

ZYCOS represents, warrants and covenants to Cohesion that ZYCOS (a) is a
corporation duly organized and in good standing under the laws of the State of
Delaware, and (b) has full power and authority and the legal right to own and
operate its property and assets and to carry on its business as it is now being
conducted and as it is contemplated to be conducted by this Agreement.

            10.3 ADDITIONAL REPRESENTATIONS, WARRANTIES AND COVENANTS OF
COHESION.

Cohesion represents, warrants and covenants to ZYCOS that:

<PAGE>

                  (a) Cohesion is corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware, and has full
corporate power and authority and the legal right to own and operate its
property and assets and to carry on its business as it is now being conducted
and as is contemplated to be conducted by this Agreement.

                  (b) Cohesion is the sole and exclusive owner of all right,
title and interest in and to the Patents listed on Schedule 10.3(b) and, except
as provided in Schedule 10.3(b), such rights are not subject to any encumbrance,
lien or claim of ownership by any Third Party. During the term of this
Agreement, Cohesion shall not encumber or diminish the rights granted to ZYCOS
hereunder.

                  (c) The conception, development and reduction to practice of
the Licensed Technology existing as of the Effective Date have not constituted
or involved the misappropriation of trade secrets or other rights or property of
any Third Party. There are no claims, judgments or settlements against or
amounts with respect thereto owed by Cohesion or any of its Affiliates relating
to the Licensed Technology. No claim or litigation has been brought or
threatened by any Person alleging, and Cohesion is not aware of any possible
claim, whether or not asserted, that (i) any of the Licensed Technology is
invalid or unenforceable or (ii) the disclosing, copying, making, assigning,
licensing or Exploiting of any of the Licensed Technology, or products and
services embodying any of the Licensed Technology, violates, infringes or
otherwise conflicts or interferes with any intellectual property or proprietary
right of any Third Party.

                  (d) Except for the grants in Section 3.1, neither Cohesion nor
any of its Affiliates has, as of the Effective Date, directly or indirectly,
expressly or by implication, by action or omission or otherwise (i) assigned,
transferred, conveyed or otherwise encumbered any right, title or interest in or
to the Licensed Technology, (ii) granted any license or other right, title or
interest in or to the Licensed Technology or the Regulatory Documentation, or
(iii) agreed to, or is otherwise bound by, any covenant not to sue for any
infringement, misuse or otherwise with respect to the Licensed Technology.

                  (e) Cohesion shall obtain from each of its Affiliates,
sublicensees, employees and agents, and from the employees and agents of its
Affiliates, sublicensees and agents, who are involved in the Exploitation of the
Licensed Technology or who otherwise have access to any ZYCOS Information or
other Confidential Information of ZYCOS, rights to any and all Information and
Inventions that relate to the Licensed Technology, such that ZYCOS shall, by
virtue of this Agreement, receive from Cohesion, without payments beyond those
required by Article IV, the licenses and other rights granted to ZYCOS and its
Affiliates hereunder.

                  (f) To the best of Cohesion' and its Affiliates' knowledge,
there is no actual or threatened infringement by a Third Party of the Licensed
Technology.

            10.4 DISCLAIMER OF WARRANTIES.

EXCEPT AS PROVIDED IN THIS ARTICLE X, COHESION MAKES NO REPRESENTATION OR
WARRANTY, EXPRESS OR IMPLIED, AS TO THE LICENSED

<PAGE>

TECHNOLOGY, OR THE VALIDITY OF SUCH TECHNOLOGY OR ANYTHING ELSE, AND THE PARTIES
HEREBY DISCLAIM ANY FURTHER WARRANTY, INCLUDING ANY WARRANTY OF MERCHANT
ABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OR OTHER STATUTORY,
IMPLIED, OR EXPRESS WARRANTIES.

                                   ARTICLE XI
                                  MISCELLANEOUS

            11.1 FORCE MAJEURE.

Neither party shall be held liable or responsible to the other party or be
deemed to have defaulted under or breached this Agreement for failure or delay
in fulfilling or performing any term of this Agreement when such failure or
delay is caused by or results from causes beyond the reasonable control of the
non-performing party, including fires, floods, embargoes, shortages, epidemics,
quarantines, war, acts of war (whether war be declared or not), insurrections,
riots, civil commotion, strikes, lockouts or other labor disturbances, acts of
God or acts, omissions or delays in acting by any governmental authority. The
non-performing party shall notify the other party of such force majeure within
ten (10) days after such occurrence by giving written notice to the other party
stating the nature of the event, its anticipated duration, and any action being
taken to avoid or minimize its effect. The suspension of performance shall be of
no greater scope and no longer duration than is necessary and the non-performing
party shall use commercially reasonable efforts to remedy its inability to
perform; provided, however, that in the event the suspension of performance
continues for one-hundred and eighty (180) days after the date of the
occurrence, and such failure to perform would constitute a material breach of
this Agreement in the absence of such force majeure, the non-performing party
may terminate this Agreement pursuant to Section 8.2 by written notice to the
other party.

            11.2 ASSIGNMENT.

Without the prior written consent of the other party hereto, neither party shall
sell, transfer, assign, delegate, pledge or otherwise dispose of, whether
voluntarily, involuntarily, by operation of law or otherwise, this Agreement or
any of its rights or duties hereunder; provided, however, that either party may,
without such consent, assign this Agreement and its rights and obligations
hereunder to an Affiliate, to the purchaser of all or substantially all of its
assets or business or stock related to the Method and the Products, or to its
successor entity or acquirer in the event of a merger, consolidation or change
in control of such party. Any attempted assignment or delegation in violation of
the preceding sentence shall be void and of no effect. All validly assigned and
delegated rights and obligations of the parties hereunder shall be binding upon
and inure to the benefit of and be enforceable by and against the successors and
permitted assigns of ZYCOS or Cohesion, as the case may be.

            11.3 SEVERABILITY.

If any provision of this Agreement is held to be illegal, invalid or
unenforceable under any present or future law, and if the rights or obligations
of any party under this Agreement will not

<PAGE>

be materially and adversely affected thereby, (a) such provision shall be fully
severable, (b) this Agreement shall be construed and enforced as if such
illegal, invalid or unenforceable provision had never comprised a part hereof,
(c) the remaining provisions of this Agreement shall remain in full force and
effect and shall not be affected by the illegal, invalid or unenforceable
provision or by its severance herefrom, and (d) in lieu of such illegal, invalid
or unenforceable provision, there shall be added automatically as a part of this
Agreement a legal, valid and enforceable provision as similar in terms to such
illegal, invalid or unenforceable provision as may be possible and reasonably
acceptable to the parties herein. To the fullest extent permitted by applicable
law, each party hereby waives any provision of law that would render any
provision hereof prohibited or unenforceable in any respect.

            11.4 GOVERNING LAW.

This Agreement shall be governed by and construed in accordance with the laws of
the State of Delaware, without reference to the rules of conflict of laws
thereof.

            11.5 NOTICES.

All notices or other communications that are required or permitted hereunder
shall be in writing and delivered personally, sent by facsimile (and promptly
confirmed by personal delivery, registered or certified mail or overnight
courier as provided herein), sent by nationally-recognized overnight courier or
sent by registered or certified mail, postage prepaid, return receipt requested,
addressed as follows:

            If to ZYCOS, to:

                   ZYCOS Inc.
                   44 Hartwell Avenue
                   Lexington, MA 02421
                   Attention: Mark A. Philip, CEO
                   Facsimile: 781-274-0839

                   with a copy to:

                   James C. Snipes
                   Covington & Burling
                   601 California St., Suite 1900
                   San Francisco, CA  94108
                   Facsimile: 415-591-6091

            If to Cohesion, to:

                   Cohesion Technologies, Inc.
                   2500 Faber Place
                   Palo Alto, California 94303
                   Attention:  Chief Executive Officer
                   Facsimile: 650-320-5533

<PAGE>

                   with a copy to:

                   -----------------------------------

                   -----------------------------------

                   -----------------------------------
                   Attention:
                             -------------------------
                   Facsimile:
                             -------------------------

or to such other address as the party to whom notice is to be given may have
furnished to the other party in writing in accordance herewith. Any such
communication shall be deemed to have been given (a) when delivered, if
personally delivered or sent by facsimile on a business day, (b) on the business
day after dispatch, if sent by nationally-recognized overnight courier, and (c)
on the third business day following the date of mailing, if sent by mail. It is
understood and agreed that this Section 11.5 is not intended to govern the
day-to-day business communications necessary between the parties in performing
their duties, in due course, under the terms of this Agreement.

            11.6 DISPUTE RESOLUTION.

                  (a) Dispute Procedures. Any dispute between the parties in
connection with or relating to this Agreement or any document or instrument
delivered in connection herewith shall first be referred to the chief executive
officers of the parties. Disputes between the parties that are not resolved by
the chief executive officers within fifteen (15) days after being referred
thereto shall be referred to compulsory arbitration in accordance with the
Commercial Arbitration Rules of the American Arbitration Association to be held
in Boston, Massachusetts. The arbitrator shall be appointed in accordance with
the Commercial Arbitration Rules of the American Arbitration Association. Any
fees and expenses payable with respect to the arbitration shall be borne by the
party losing the case. All arbitration rulings and awards shall be final and
binding on the parties. Notwithstanding any of the foregoing, if the arbitrator
appointed pursuant to this Section 11.6(a) is unable or unwilling to resolve the
dispute for which such arbitrator is appointed within one hundred and eighty
(180) days of such appointment, the parties shall be free to seek any available
judicial remedy.

                  (b) Interim Relief. Notwithstanding anything herein to the
contrary, nothing in this Section 11.6 shall preclude either party from seeking
interim or provisional relief, including a temporary restraining order,
preliminary injunction or other interim equitable relief concerning a dispute,
either prior to or during the arbitration, if necessary to protect the interests
of such party. This Section 11.6 shall be specifically enforceable.

            11.7 ENTIRE AGREEMENT; MODIFICATIONS.

This Agreement sets forth and constitutes the entire agreement and understanding
between the parties with respect to the subject matter hereof and all prior
agreements, understanding, promises and representations, whether written or
oral, with respect thereto are superseded hereby. Each party confirms that it is
not relying on any representations or warranties of the

<PAGE>

other party except as specifically set forth herein. No amendment, modification,
release or discharge hereof shall be binding upon the parties unless in writing
and duly executed by authorized representatives of both parties.

            11.8 RELATIONSHIP OF THE PARTIES.

It is expressly agreed that Cohesion, on the one hand, and ZYCOS, on the other
hand, shall be independent contractors and that the relationship between the two
parties shall not constitute a partnership, joint venture or agency. Neither
Cohesion, on the one hand, nor ZYCOS, on the other hand, shall have the
authority to make any statements, representations or commitments of any kind, or
to take any action, which shall be binding on the other, without the prior
written consent of the other party to do so. All persons employed by a party
shall be employees of such party and not of the other party and all costs and
obligations incurred by reason of any such employment shall be for the account
and expense of such party.

            11.9 EQUITABLE RELIEF.

Cohesion acknowledges and agrees that the restrictions set forth in Article VII
of this Agreement are reasonable and necessary to protect the legitimate
interests of ZYCOS and that ZYCOS would not have entered into this Agreement in
the absence of such restrictions, and that any violation or threatened violation
of any provision of Article VII will result in irreparable injury to ZYCOS.
Cohesion also acknowledges and agrees that in the event of a violation or
threatened violation of any provision of Article VII, ZYCOS shall be entitled to
seek preliminary and permanent injunctive relief, without the necessity of
proving irreparable injury or actual damages and without the necessity of having
to post a bond, as well as to an equitable accounting of all earnings, profits
and other benefits arising from any such violation. The rights provided in the
immediately preceding sentence shall be cumulative and in addition to any other
rights or remedies that may be available to ZYCOS. Nothing in this Section 11.9
is intended, or should be construed, to limit ZYCOS's right to preliminary and
permanent injunctive relief or any other remedy for a breach of any other
provision of this Agreement.

ZYCOS acknowledges and agrees that the restrictions set forth in Article VII of
this Agreement are reasonable and necessary to protect the legitimate interests
of Cohesion and that Cohesion would not have entered into this Agreement in the
absence of such restrictions, and that any violation or threatened violation of
any provision of Article VII will result in irreparable injury to Cohesion.
ZYCOS also acknowledges and agrees that in the event of a violation or
threatened violation of any provision of Article VII, Cohesion shall be entitled
to seek preliminary and permanent injunctive relief, without the necessity of
proving irreparable injury or actual damages and without the necessity of having
to post a bond, as well as to an equitable accounting of all earnings, profits
and other benefits arising from any such violation. The rights provided in the
immediately preceding sentence shall be cumulative and in addition to any other
rights or remedies that may be available to Cohesion. Nothing in this Section
11.9 is intended, or should be construed, to limit Cohesion's right to
preliminary and permanent injunctive relief or any other remedy for a breach of
any other provision of this Agreement.

<PAGE>

            11.10 WAIVER.

Any term or condition of this Agreement may be waived at any time by the party
that is entitled to the benefit thereof, but no such waiver shall be effective
unless set forth in a written instrument duly executed by or on behalf of the
party waiving such term or condition. The waiver by either party hereto of any
right hereunder or of the failure to perform or of a breach by the other party
shall not be deemed a waiver of any other right hereunder or of any other breach
or failure by said other party whether of a similar nature or otherwise.

            11.11 COUNTERPARTS.

This Agreement may be executed in two (2) or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and
the same instrument.

            11.12 NO BENEFIT TO THIRD PARTIES.

The representations, warranties, covenants and agreements set forth in this
Agreement are for the sole benefit of the parties hereto and their successors
and permitted assigns, and they shall not be construed as conferring any rights
on any other Persons.

            11.13 FURTHER ASSURANCE.

Each party shall duly execute and deliver, or cause to be duly executed and
delivered, such further instruments and do and cause to be done such further
acts and things, including the filing of such assignments, agreements, documents
and instruments, as may be necessary or as the other party may reasonably
request in connection with this Agreement or to carry out more effectively the
provisions and purposes hereof, or to better assure and confirm unto such other
party its rights and remedies under this Agreement.

            11.14 REFERENCES.

Unless otherwise specified, (a) references in this Agreement to any Article,
Section or Schedule shall mean references to such Article, Section or Schedule
of this Agreement, (b) references in any section to any clause are references to
such clause of such section, and (c) references to any agreement, instrument or
other document in this Agreement refer to such agreement, instrument or other
document as originally executed or, if subsequently varied, replaced or
supplemented from time to time, as so varied, replaced or supplemented and in
effect at the relevant time of reference thereto.

            11.15 CONSTRUCTION.

Except where the context otherwise requires, wherever used, the singular shall
include the plural, the plural the singular, the use of any gender shall be
applicable to all genders and the word "or" is used in the inclusive sense. The
captions of this Agreement are for convenience of reference only and in no way
define, describe, extend or limit the scope or intent of this Agreement or the
intent of any provision contained in this Agreement. The term "including" as
used herein shall mean including, without limiting the generality of any
description preceding such term. The

<PAGE>

language of this Agreement shall be deemed to be the language mutually chosen by
the parties and no rule of strict construction shall be applied against either
party hereto.

            11.16 LIMITATION ON DAMAGES.

SUBJECT TO ARTICLE IX HEREOF, AND EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR
INTENTIONAL MISCONDUCT, NONE OF ZYCOS, COHESION OR ANY OF THEIR RESPECTIVE
AFFILIATES SHALL BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL
DAMAGES (INCLUDING FOR LOST PROFITS, MILESTONES OR ROYALTIES), WHETHER IN
CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT
OF (a) THE EXPLOITATION OF ANY PRODUCT PURSUANT TO THE TERMS OF THIS AGREEMENT,
OR (b) ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS
AGREEMENT.

                           [SIGNATURE PAGE TO FOLLOW]

<PAGE>

            IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed by their duly authorized representatives as of the date first above
written.

COHESION TECHNOLOGIES, INC.                  ZYCOS INC.

By: /s/ William G. Mavity                    By: /s/ Mark A. Philip
    --------------------------                   --------------------------
Name: William G. Mavity                      Name: Mark A. Philip
      ------------------------                     ------------------------
Title: President / CEO                       Title: President & CEO
       -----------------------                      -----------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]